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ABSTRACT

Prostate cancer is the second leading cause of cancer-related deaths in
men in the United States. The molecular pathogenesis of this disease includes
genetic alterations, infection, and exposure to inflammatory or dietary oxidants.
Recently, research has focused on the role of host defense peptides in tumor
immunity. Defensins, a highly conserved multigene family of proteins that
possess antimicrobial and antiviral properties, play an essential role in innate and
adaptive immunity. These peptides are categorized into alpha- and betadefensins based upon the spacing and connection between the six conserved
cysteine residues of the mature peptide. Human Beta Defensin-1 (hBD-1), an
important component of the innate immune system, is frequently lost in malignant
prostate tissue, while expression is maintained in adjacent benign regions.
Several studies indicate there may be multiple tumor suppressor genes present
within the 8p22-23 region in prostate carcinoma, an area where frequent genetic
alterations occur. The high incidence of loss of hBD-1 expression in prostate
cancer, along with its chromosomal location of 8p23.2, raised the possibility that
it may playa role in tumor suppression. Our studies demonstrated that induction
of hBD-1 expression results in significant changes in cell viability, membrane
permeability, and the activation of caspase-mediated apoptosis in DU145 and
PC3 human prostate cancer cell lines. However, no effect was observed
following the induction of hBD-1 in LNCaP. To gain insight into the caspasemediated cell death, we analyzed the activation of specific caspases within the
intrinsic and extrinsic pathway following the induction of hBD-1 expression. In

xv

DU145 and PC3 prostate cancer cell lines the activation of both apoptotic
pathways was observed, specifically the activation of caspases 3, 8 and 9.
However, no caspase activation was observed in the LNCaP prostate cancer cell
line. Although our studies suggest that within our expression system and
employed methodologies, hBD-1 does not exhibit a 'bystander effect' on
neighboring cells, the results indicate a possible upward trend suggesting that
hBO-1 may exhibit a 'bystander effect' under different conditions than those used
in this study. Collectively, this data indicates the loss of hBD-1 in the area
surrounding prostate cancer cells may create an environment that promotes the
progression of prostate cancer.
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CHAPTER 1
INTRODUCTION

Prostate cancer continues to be a major burden on public health with high
incidence of diagnosis and cancer-related deaths as compared to other forms of
cancer. In South Carolina, it is the most commonly diagnosed cancer among
males regardless of race 1. However, the incidence rate is almost two times
higher in black males as white males1. In addition, prostate cancer is the second
leading cause of cancer-related deaths among South Carolina men with mortality
rates due to prostate cancer being three times higher in black males1. The
current methods of early detection include the prostate specific antigen test
(PSA), the digital rectal exam (DRE), and the diagnostic tissue biopsy. Although
together these methods have helped diagnose prostate cancer at earlier stages
in the general population over the years2,

3,

they have marked deficiencies.

Consequently, a better understanding of the molecular pathogenesis of prostate
cancer may lead to the identification of pre-malignant molecular biomarkers that
accurately predict neoplastic transformation within the prostate.

The pathobiologyof prostate cancer is multifaceted due to the altered
expression of numerous genes

4

,

as well as environmental factors such as

inflammation and dietS allowing for a multitude of potential biomarkers. A
therapeutic target and potential biomarker of prostate cancer we are exploring is
human Beta Defensin-1 (hBD-1). We previously demonstrated the cancerspecific loss of innate immune peptide hBD-1, with a chromosomal location of
8p23.2, in prostate cancer6. Several cytogenetic studies have demonstrated
deletions on the short arm of chromosome 8 in a variety of cancers, including
carcinomas of the bladder 7 , liver8 , ovary9, and prostate 10-16. Since the location of
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tumor suppressor genes (TSGs) is suggested by the homozygous deletion of
chromosomal regions 17 , it has been proposed that the 8pter-8p23 region contains
at least three separate tumor suppressor genes18- 20 . The high incidence of loss of
hBD-1 expression in prostate cancer, along with its chromosomal location, raised
the possibility that it may be a tumor suppressor gene.
In addition to the loss of TSGs, prostate tumor progression has also been
associated with an increase in immune suppression in patients 21 . In addition, it
has been suggested that a tumor is capable of escaping destruction by the
immune system via disruptions in the activation and suppression of immunity
during tumor growth 22 • Even though little is known about specific components of
the immune system involved in tumor suppression, the loss of hBD-1 expression
suggested that it may be a component of a tumor surveillance system that
functions specifically through tumor immunity. Therefore, a better understanding
of the expression pattern and role of hBD-1 in prostate cancer will give a more
complete picture of precisely how this antimicrobial peptide is involved in the
progression of prostate cancer.
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CHAPTER 2
BACKGROUND AND SIGNIFICANCE:
A REVIEW OF THE LITERATURE
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The Prostate Gland
The prostate gland is a walnut-sized organ that functions as part of the
male reproductive system. It is located in the pelvic area in front of the rectum
and underneath the bladder (Figure 2-1). In addition, the prostate encompasses
a portion of the urethra com ing from the bladder known as the prostatic urethra
that merges with two ejaculatory ducts.
Heterogenous in nature, the prostate is divided into glandular and nonglandular tissues. The glandular components include the ducts and glands, while
the non-gladular components consist of fibromuscular tissue. Pathologically the
prostate is classified by four zones: the peripheral zone, the central zone, the
transition zone, and the anterior zone 23 • The peripheral zone is the closest to the
rectum and accounts for the largest portion of prostatic volume. This zone is
where the largest percentage of prostate cancers originate 23 • Comprising the
second largest portion of the prostate volume, the central zone surrounds the
ejaculatory ducts. The smallest and innermost glandular component of the
prostate, the transition zone, surrounds the prostatic urethra and is rarely
associated with cancer. The anterior zone, closest to the abdomen and
composed mainly of fibromuscular tissue, consists of the non-glandular
components of the prostate.
In younger males the prostate is generally healthy, however, as a man
ages changes begin to occur within the gland (Figure 2-2). These changes
mainly present in a clinical setting as one of three main prostate
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Figure 2-1: Illustration of the location of the prostate gland. The prostate is

a part of the male reproductive system that encompasses a portion of the
prostatic urethra. (adapted from www.cancer.gov)

Figure 2-1: Illustration of the location of the prostate gland.
(adapted from www.cancer.gov)
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Figure 2-2: Schematic of changes from normal prostate to prostate cancer.
A histologic account for the changes from a healthy prostate typical of a young
male that lead to prostate cancer. (adapted from Nelson et a1200326 )
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Figure 2-2: Schematic of changes from normal prostate to prostate cancer.
(adapted from Nelson et al 200326 )
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disorders: prostatitis, hyperplasia or carcinoma. The first of these changes is
prostatitis, or inflammation of the prostate tissue, which manifests as difficult or
painful urination. It is classified as acute or chronic based upon a combination of
clinical features and microscopic examination. Although the cause is often
unknown, it is sometimes a result of a bacterial organism associated with other
urinary tract infections21.
Another change that can occur with age in the prostate is enlargement of
cells within the transition zone, also know as benign prostatic hyperplasia
(BPH)24. As the prostate enlarges, it begins to squeeze the urethra which may
cause urinary problems by slowing or obstructing the flow of urine from the
bladder to the penis. Additionally, BPH can result in retention of urine in the
bladder due to the inability to completely empty it. Neither prostatitis nor BPH
are known to cause cancer, however, men with one or both of these conditions
may develop prostate cancer as well.

Prostate Cancer
Prostate cancer remains the most common malignancy, excluding skin cancer,
and the second leading cause of cancer related deaths in men in the United
5tates25 . Risk factors for prostate cancer that have long been recognized include
age, race, androgens and a variety of lifestyle factors, such as diet. In addition,
there is a strong hereditary component in the risk of prostate cancer
development. Steinberg et al. (1990) reported that the number of affected first-
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degree relatives significantly increased the risk, whereas there was only a
marginal increase in risk if distant relatives were affected 27 .
More recently, molecular genetic studies of fam ilial prostate cancer led to
the identification of numerous genes and genetic alterations that has greatly
enhanced our understanding of prostate cancer development and progression 4 .
The most thoroughly investigated of these is hereditary prostate cancer (HPC1
gene)28. In addition, it has been proposed that RNASEL, MSR1, AR, CYP17,
SRD5A2, and a variety of other genes are potential contributors to the risk of
prostate cancer developmenf9-36 . Although the exact mechanism underlying
prostate tumorigenesis is unknown, it is known that the clinical outcome of a
prostate cancer patient is closely related to tumor grade and stage with poorly
differentiated tumors having a poor prognosis37 .

Molecular Pathogenesis of Prostate Cancer
The molecular pathogenesis of prostate cancer involves a progression
through a series of pre-malignant changes that ultimately lead to uncontrolled
cellular division resulting in malignancy (Figure 2-3). There is an abundance of
evidence suggesting a key component of this progression includes the
transformation of normal epithelium to prostate inflammatory atrophy (PIA), a
focal area of proliferating cells accompanied by inflammation 38 . PIA lesions
occur in the peripheral zone of the prostate where most prostate carcinomas
originate 38 , 39 and are often located adjacent to areas of prostate intraepithelial
neoplasms (PIN), a known precursor to prostate cancer40 .
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Figure 2-3: Pathogenesis of prostate cancer. The effects of age and the
accumulation of numerous genetic and environmental insults that contribute to
the molecular pathogenesis of prostate cancer. (adapted from Nelson et al
20044°)
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Figure 2-3: Pathogenesis of prostate cancer.
(adapted from Nelson et al 20044 °)
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Several studies have identified additional changes in prostate tissue as it
undergoes a transition from PIA to PIN including p53 mutations41 and "-class
glutathione S transferase (GSTP) hypermethylations38 , 42, GSTs, long
recognized to protect against cancer, are a fam ily of enzymes that prevent DNA
damage by serving as a catalyst for the scavenger glutathione to detoxify
environmental carcinogens and oxidants43 , 44, The loss of GSTP1 expression
due to hypermethylation and the inflammatory state of PIA lesions have been
associated with high grade PIN 26 , 40,45,46,
The term PIN refers to established morphological criteria that simply
defined describes the presence of individual, atypical cells resulting in the
enhancement of the normal glandular architecture 4 , Multiple studies indicate that
areas within the prostate that demonstrate the histological changes of PIN are
designated as low or high grade based upon the findings47 • It is important to note
that current models of the molecular pathogenesis of prostate cancer recognize
PIN as a precursor to the development of prostate cancer48 •
As in other forms of cancer, prostate neoplasms have been extensively
studied for genetic alterations and candidate susceptibility genes49 , Loss of
heterozygosity (LOH) describes the loss of one allele in the tumor cells of a
heterozygous individual. LOH studies in various types of cancer have identified
the loss of putative tumor suppressor genes5 , 6, Although the underlying
mechanism of LOH is not completely understood, several proposed mechanisms
include the loss of whole chromosomes, partial chromosome deletion,
disproportionate translocation and mitotic recombination 36 , 40, 50-53, Studies have
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shown that chromosome 8 possesses the most frequent cytogenetic changes
observed in prostate cancer patients54 , 55.
To date, at least three host immune response genes are emerging as
prostate cancer susceptibility genes: RNASEL, MSR1, and hBD-1 35 , 36.
RNASEL, a ribonuclease activated in the presence of viral infections, functions to
degrade cellular and viral RNA. Studies have identified three mutant alleles of
RNASEL that result in a defective protein and have been associated with
increased prostate cancer risk 50-52 •
Another immune response gene that has emerged with a strong
association to prostate cancer development is MSR1 56 , 57. Located on 8p22, the
MSR1 gene encodes a macrophage scavenger protein that can bind various
ligands, including bacteriallipopolysaccharides26 . It appears the expression of
MSR1 is limited to macrophages at sites of inflammation within the prostate.
Lastly, the cancer specific loss of hBD-1 has been shown in prostate and
renal carcinomas58 , 59. In addition, several studies have demonstrated that the
over-expression of this peptide results in cell death in prostate, bladder, and
renal cancer celilines6o-62 • Although the exact mechanisms of these genes
involvement in prostate cancer pathogenesis are unknown, the data suggest it
involves host defense against inflammatory damage. Moreover, the genetic
changes observed in and molecular pathogenesis of prostate cancer provide
ample evidence for the role prostate inflammation may play in the development
of prostate cancer.
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Prostate Cancer Detection
Since the mid-1990's, the measurement of prostate specific antigen (PSA)
levels has been one of the main screening methods for prostate cancer. PSA is
a serine protease normally present in the acidic fluid secreted in the semen. On
average, a PSA level is normal if it falls below 4ng/ml and high if it is above
10ng/ml. Elevated serum PSA levels or the palpitation of a tumor growth during
a digital rectal exam (ORE) are considered to be prognostic indicators of prostate
carcinoma.
Although these methods have served to increase the detection of prostate
cancer, they have recognized limitations. The DRE, a quick, but rather invasive
physical exam, allows for an area of detection limited to digital palpitation, thus,
leaves room to miss a tumor. While the PSA screening serves to detect potential
prostate cancer missed by the DRE, it has inherent problems with sensitivity and
standardization. For example, an increase in PSA levels can be a result of other
abnormalities of the prostate such as prostatitis or BPH 63 . Therefore, it is
necessary to perform a transrectal biopsy to confirm a clinical diagnosis. Since
none of the methods to date have proven to definitively diagnose prostate cancer
alone, the emergence of new molecular targets may prove to identify early
alterations in prostate cells accurately and efficiently with minimal invasiveness.

Prostate Cancer Grading System
Several histopathological grading systems for prostate cancer have been
designed. However, the Gleason grading system, named after D.F. Gleason,
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was recommended by a WHO consensus conference in 1993 and is currently the
principal grading system used 64 . The Gleason grading system defines the
histological patterns with decreasing differentiation in glandular architecture of
the tissue 65 , 66. To obtain a Gleason score, the primary and secondary, i.e. most
prevalent and second most prevalent, patterns are added 66 . Gleason pattern 1
tumors are very rare and composed of a well confined nodule of separate, tightlyassociated glands that do not infiltrate into adjacent benign tissue 67 . Gleason
pattern 2 describes rounded glands with smooth ends that are loosely arranged
and lack the uniform size67 . The most common is Gleason pattern 3, in which
there is more glandular infiltration of adjacent benign tissue, as well as a more
marked variation of distance between them 67 . In Gleason pattern 4, the glands
are fused and no longer have stroma separating them, while Gleason pattern 5
describes almost a complete loss of glandular lumina 67 .

The Defensin Family
Antimicrobial peptides (AMPs) are found in an extensive array of
68
eukaryotic organisms and are classified into categories based upon their
structural characteristics69 . One important category of AMPs in humans is the
defensin family70-72. Defensins, a family of 3-4 kDa cationic peptides, are
cysteine rich amphipathic peptides involved in innate immunity73. They can be
classified into a-,

p- and 9-defensins based on the pattern of six conserved

cysteine residues and the precursor gene structure 74 . a-defensins are normally
abundant in the microbicidal granules of polymorphonuclear leukocytes and have
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been identified in the Paneth cells of the human intestine 75 . p-defensins have
been identified in bovine tracheal epithelium 76 and the epithelial surfaces of
respiratory, genitourinary, and gastrointestinal tracts 77 , 78. Although a-defensins
exhibit broad spectrum antimicrobial activity against both Gram-negative and
Gram-positive bacteria, fungi, and enveloped viruses 79 , p-defensins are mainly
active against Gram-negative bacteria and yeast59 , 60, 80.
To be classified as a p-defensin, the peptide must consist of 36 or more
amino acids with a primary structure that consists of the following identifiable
disulfide bond sequence 1-5,2-4, and 3_6 73 ,81-83. Other residues that are
conserved among the p-defensins include (using hBD-1 numbering): Gly10, a
cationic residue at position 13, Glu21, and hydrophobic residues at positions 24
and 36 81 . The carboxy terminal end of the four most studied hBDs, hBD-1 to
hBD-4, contains a cluster of cationic residues (Lys and Arg). The aggregation of
positive charges proves to be important for antimicrobial activity73.
To date, six hBDs (hBD1-6) have been identified that are either
constitutively secreted, or inducibly expressed for secretion, at the epithelial cell
surface84, 85. The first human p-defensin, hBD-1, was purified from the plasma of
patients with renal disease in 199586 ,87. Since then, several other p-defensins
have been isolated or identified through genetic analysis. hBD-2 was purified
from the lesions of psoriatic skin 88 , 89, while hBD-3 was isolated from psoriatic
scales90, 91. The remaining three p-defensins identified to date, hBDs 4-6, were
originally reported based upon genome analysis62 , 75. Searches of the human
genome have recently revealed about 40 potential coding regions for p-defensins
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(DEFBs)91 suggesting the possibility that numerous hBDs have yet to be isolated
and identified.
Currently there are two postulated mechanisms of how host defense
peptides exhibit the antibacterial properties they posses (Figure 2_4)92: the barrel
stave model and the carpet model. The models are based upon the selectivity of
the peptide for its binding surface.

(1) Barrel stave model: In this model, multimeric pores form
as a result of the hydrophobic bond between the peptide and the
bacterial cell membrane in a non-selective manner91. More
specifically, the hydrophobic surface of lytic peptide monomers
interacts with the lipid core of the bacterial membrane causing the
hydrophilic surface to point inward forming an aqueous pore.
Recruitment of additional monomeric peptides to the site leads to
an increase in the pore size eventually resulting in membrane
depolarization ad cell death 93 .
(2) Carpet model: This model describes the cell selective
electrostatic interaction of the AMPs to the surface of the outer
membrane. The peptides cover the membrane surface like a
carpet until reaching a threshold concentration which enables the
peptides to permeate the membrane. Permeation results in an
intermediate formation of transient pores, known as 'toroidal' pores,
that span the distance of the membrane 95, 96. Cell death follows
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Figure 2-4: Illustrations of the two mechanisms of membrane lysis by host
defense peptides. Peptides that are not cell-selective bind to all types of
membranes and form transmembrane pores via the 'barrel-stave' mechanism
resulting in membrane depolarization followed by cell death. Peptides that are
cancer cell-selective bind in the first step mainly by electrostatic interactions and
align parallel to the outer membrane surface (step 1) and cover it in 'carpet-like

J

manner. After a threshold concentration of peptides has been reached (step 2),
the peptides permeate the membrane, which, in most cases, is followed by
membrane disintegration and micellization. An intermediate step is the formation
of transient pores. These pores were described as !toroidal' pores for peptides
that are long enough to span the membrane. These pores might also lead
directly to cell death. The figure also shows B 16 me\anoma ce\\s treated w\th a
lytic peptide labeled with rhodamine before (picture on the left showing the intact
cell) and after (pictures on the right showing the remaining nucleus) a threshold
concentration has been reached. (adapted from Papo and Shai 2005 94 )
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.. embrnne depohuization
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Figure 2-4: Illustrations of the two mechanisms of
membrane lysis by host defense peptides. (adapted from
Papo and Shai 2005 94 )
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pore formation due to the disintegration of the membrane and
micellization 97 ,98.
The proposed mechanism of p-defensin action against invading pathogens
follows the carpet model with electrostatic interactions occurring between the
basic defense peptides and the acidic phospholipids on the bacterial
membrane99 . Although the basic carpet model is accepted, several views exist
that expound upon the mechanistic details of the process.
As previously mentioned, an AMP selectively targets based upon the
composition of the cell membrane. Bacterial cell membranes consist of
phospholipids with negatively charged outer leaflets, while the outer leaflet of
eukaryotic cell membranes contains phospholipids consisting of mainly neutral
choline 91 . It has been shown that defensins selectively target tumor cells
compared to non-transformed cells 100 . There are several possible explanations
for the selective targeting of tumor cells. Compared to a normal eukaryotic cell, a
transformed cell has a slightly negative charge on the outer membrane due to the
presence of phosphatidylserine and O-glycosylated mucine 101. In addition, a
tumor cell exhibits a partial loss of its lipid asymmetry, thus, contributing to the
slight negative charge it devel ops102, 103. The transition from neutral to negatively
charged allows the tumor cell to be more susceptible to the lytic effects of the
peptides without harmful effects to surrounding normal cells. Another
explanation for the difference in susceptibility between tumor and normal cells in
response to lytic peptides may be the presence of more microvilli which provides
an increased surface area on tumor cells that allows for the binding of a greater
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number of peptides94 , 104, 105. A final explanation for the difference may be that
tumor cells have a higher negative potential than non-transformed cells85 .
Numerous reports indicate the importance of the antimicrobial action that
defensins exhibit as part of the immune response. A demonstration of their
significance centers on a correlation between defensin expression and the
incidence of infection in humans106,107. It was recently reported that a decrease
in p-defensin expression in atopic dermatitis contributed to the presence of skin
infections 106,108. Similarly, other reports indicate a reduction in defensin
expression contributes to the chronic bacterial infections experienced by cystic
fibrosis patients6, 96, 109, 110.
Although the main function of defensins is to serve as the initial response
to a pathogen as a critical part of innate defense 111 , they exhibit many other
properties 112(Figure 2-5). Studies have been conducted to investigate defensin
mediated immune activation, IL-8 production, and chemotaxis of iDG and Tcells 113. It has also been shown that there are inter-individual variations in
expression of p-defensins modulated in response to infection and
inflammation 114.
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Figure 2-5: Diagram of the various biological functions of p-defensins.
Peptides of the p-defensin family mediate and participate in a variety of biological
functions. These processes are both microbicidal and non-microbicidal in nature.
(adapted from Kluver, et al 2006 106 )

Figure 2-5: Diagram of the various biological functions of p-defensins.
(adapted from Kluver et al. 2006 106)
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The field of tumor immunity is gaining more attention lately as the
convergence of tumorigenesis and immunity has created an exciting and
promising area of research. It has been shown that in oral squamous cell
carcinoma, lung cancer, basal cell carcinoma, renal and prostate carcinomas Pdefensins exhibit differential gene expression profiles115, 116. The manipulation of
the immune system to destroy tumor cells was initially described by Morales et

a/. in 1976 with the anti-tumor effect of Mycobacterium bovis Bacillus CalmetteGuerin (BCG) in bladder cancer116. Recently, Ludwig et a/ published data
supporting the antitumoral activity of BCG therapy is due to the response of
cytokines to BCG, ultimately leading to the upregulation of tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL)77, 117. TRAIL has been shown to
induce apoptosis in multiple cancer cells without exhibiting cytotoxicity to normal
cells22 •
In addition, growing evidence supports anti-cancer therapies using
monoclonal antibodies (mAbs) to specifically target cancer cells without
disrupting surrounding normal tissue 118 . Other immune-based therapies, such as
cytokine and vaccine approaches, have been used in clinical trials as a treatment
for a variety of cancers, including prostate cancer78 . Fong et al. (2001) have
shown that antigen-specific antitumor immune response can be initiated through
the use of dendritic cells as a vector for presenting tumor antigens81 , 85.
The Gj-protein-coupled receptor, CCR6, mediates the recruitment of iDCs
and memory T cells for p-defensins indicating their activity in adaptive immunity.
Additional studies into the adaptive immune component of p-defensins have
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demonstrated they are capable of facilitating the delivery of antigens to receptors
on iDCS81 . This results in an antigen-specific immune response mediated by the
presentation of the tumor antigen to mature dendritic cells and T cells via MHC II
molecules. However, evidence exists that demonstrates dendritic cell infiltration
is decreased in patients with advanced prostate cancer, thus suggesting a
possible mechanism by which immunity-mediated destruction is suppressed in
prostatic tumors106.

Human Beta Defensin-1
Human p-defensin-1 was first isolated as a 36 amino acid peptide from
human plasma ultrafiltrates119 and has been mapped to chromosome 8p23.2 75 , 76.
The DEFB1 gene has a simple structure consisting of two exons flanking an
intron that spans 6962 bp 14,78,91,94,106 (Figure 2-6). The full length cDNA for
hBD-1 contains only 362 bases 78 , 119 (Accession No. X92744). A characteristic
endoplasmic reticulum targeting signal sequence with signal peptidase cleavage
sites between Gli 1/Gli 2 and Ser16/Glu 17 , a short (11 or 16 amino acid) propiece, and a sequence for the mature hBD-1 peptide are encoded in the open
reading frame 78 , Specifically, the 128 bp exon 1 encodes the prepro-piece,
which is about 68 amino acids in length, and the signal sequence 78 , 88,119. Exon
2, 234 bp in length, encodes the mature hBD-1 peptide 78 • 91 , A GC box is found
at position -217 bp and a TATA box sequence are located at position -34 bp
relative to the first cDNA base 78 •
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Figure 2-6: Signature motif for p-defensin genes. The structural organization
of the 3-defensin gene includes two exons surrounding a variably sized intron.
Some degree of nucleotide identity is found among the defensins in exon 1,
which encodes the signal sequence 14. Exon 2 encodes the propeptide and
mature peptide. (adapted from Weinberg et al. 199812°)
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The proteolytic processing of varying functional domains of a protein
generally occurs as needed during the maturation process. Several studies have
identified naturally occurring N-terminally truncated molecular variants of hBD-1
from 36-47 amino acids in length in blood and urine 74, 119. Mass spectrometry
measured the molecular masses of 3928 Da for the native peptide and 4276 Da
for the reduced and alkylated peptide 81 .
With the initial isolation of hBD-1 from human filtrates, it was estimated
that the peptide is present in nanomolar concentrations81 . Although it has been
shown that hBD-1 has cytotoxic potential toward mammalian cells106,119,
constitutive expression at basal levels is not sufficient to independently lyse cell
targets. It is known that hBD-1 is a constitutively expressed peptide in the
epithelia of numerous tissues, including gingival, lung, digestive, kidney, and
prostate 74 , 82,123,124. In addition, hBD-1 is the only human beta defensin the gene
expression of which is not induced by inflammatory stimuli, such as IL-8 and
LPS78, 125, 126.

Previously Donald et a/ demonstrated the cancer specific loss of hBD-1
expression in clinical prostate and renal carcinoma samples6. In addition, IHe
analysis indicated the loss of expression occurs as early as PIN, a precursor to
prostate carcinoma, with normal glandular staining observed in adjoining benign
tissue (Figure 2-7)6. Overall, they found benign epithelium stained positive for
hBD-1 expression in both the kidney and prostate, while adjacent malignant
epithelium exhibited little to no stain for hBD-1 in 90% and 82% of the samples,
respectively (Figure 2-8)6.
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Figure 2-7: IHC analysis of hBD-1 in the prostate. A, Normal prostate
expresses hBO-1 (black arrow), while adjacent malignant tissue does not (red

arrow). B, PIN exhibits loss of hBD-1 expression (red arrow), while expression is
maintained in a normal gland (black arrow). C, Malignant prostate tissue shows
the absence of hBO-1 stain (red arrow), while normal glands are positive for
hBD-1 (black arrow). (adapted from Donald et a/20036 )

(~

Figure 2-7: IHC analysis of hBD-1 in the prostate.
(adapted from Donald et a/20036 )
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Figure 2-8: Staining intensities of hBD-1 protein in kidney and prostate
cancers clinical samples. A, Prostate cancer (n=1 00); B, renal cancer (n=48).
Each graph summarizes the results of IHe staining intensity of two pathologists.
The staining intensities were determined on an individual basis according to the
percentage of malignant cells positive for hBD-1 expression as follows:
Negative= no positive cells; Weak= 1% to 250/0; Moderate= 26% to 750/0; Strong=
76% to 100%. (adapted from Donald et a/ 20036 )
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As mentioned earlier ,B-defensins function as antimicrobial or chemotactic
agents. However, numerous studies have demonstrated the rather weak
antimicrobial 119 and chemotactic 77. 127 activities of hBD-1 as compared to other
family members suggesting other biological functions. Recently, the strong
cytotoxicity of hBD-1 in vitro against multiple cancer cell lines has been
demonstrated56, 57. Given that endogenous hBD-1 is constitutively expressed by
normal cells without cytotoxicity, it may be distinct phenotypic characteristics that
render tumor cells sensitive to the cytotoxiC effects of hBD-1. Thus, it is a
plausible suggestion that hBD-1 plays a critical role in tumor immunity.

Hypothesis, Specific Aims and Significance
Although it is known that innate immunity is key for protecting the body
against foreign agents such as bacteria, little is known about elements of the
innate immune system that have anti-tumor activity. hBD-1, an important
component of the innate immune response, is lost at high frequencies in
malignant prostatic tissue, while expression is maintained in adjacent benign
regions 14. In prostate carcinoma, frequent genetic alterations occur in the 8p2223 region and several studies indicate there may be multiple tumor suppressor
genes present within this region 21 , 128.129, The high incidence of loss of hBO-1
expression in prostate cancer, along with its chromosomal location of 8p23.2,
raised the possibility that it may playa role in tumor suppression. Therefore, we
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hypothesize that hBD-1 may be a tumor suppressor gene involved in tumor
immunity in prostate cancer.

To test this hypothesis, we propose the following specific aims:

Specific Aim 1: Characterize the effects of ectopic expression of hBO-1 on
prostate cancer cell lines.

The hBD-1 gene has been cloned into an inducible expression system that will
be utilized to characterize its function in prostate cancer cells. This will be
determined by examining the effect hBD-1 has on cell viability, as well as
morphological changes to cell membrane and annexin Vand propidium iodide
uptake in cells induced for hBD-1 expression.

Specific Aim 2: Determine the cellular mechanisms associated with the
effects of hBD-1 on prostate cancer cells.

The inducible hBD-1 expression system will be utilized to determine if hBD-1
induces apoptosis in prostate cancer cells. This will be determined by analysis of
caspase activation and changes in the expression of various regulators of
apoptosis, such as BCL-2 family members and AKT.

Specific Aim 3: Determine the role of hBD-1 in the progression of prostate
cancer.
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Here, we will determine if hBD-1 functions as a component of a tumor
surveillance system by acting on neighboring cells via a 'bystander effect.' The
cell culture supernatant exposed to normal prostate epithelial cells will be
harvested and analyzed for secretion of hBD-1 peptide. Additionally, the
expression of hBD-1 will be profiled in prostate tissue samples from benign,
tumor and areas of PIN.

Significance:
Numerous studies have indicated the importance of chromosome 8
instability in prostate tumorigenesis 22 . The goal of this proposal is to characterize
the function of hBD-1, an important component of the innate immune response
that is lost in prostate cancer. Since the gene encoding hBD-1 is located within a
region of chromosome 8p thought to contain three separate tumor suppressor
genes130 , the studies will focus on hBD-1 as a potential tumor suppressor in
prostate cancer. The proposed aims will allow further understanding how hBD-1
functions in prostate cancer and may eventually aid in the development of
strategies to prevent prostate cancer incidence and mortality.
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CHAPTER 3
CHARACTERIZATION OF THE EFFECTS OF HBD-1
ON PROSTATE CANCER CELLS
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INTRODUCTION

Prostate cancer is the most common non-cutaneous malignancy in
American men and is the second leading cause of cancer-related death in males
in the United States 131. The clinical outcome of prostate cancer is closely related
to tumor grade and stage, with poorly differentiated tumors having a poor
prognosis131. Prostate tumor progression has been linked to an increase in
immune suppression in prostate cancerpatients6 • It has also been suggested
that an imbalance between immune activation and suppression during tumor
growth allows a tumor to escape immune destruction 132. However, little is known
about specific components of the innate immune system that playa role in
prostate tumor suppression.
The defensin genes, a family of 3-4 kDa polycationic peptides clustered on
the short arm of chromosome 8 at segment 8p22-8p23, have been shown to act
as antimicrobial agents by disrupting membrane integrity resulting in cell lysis
and death 6 . The involvement of defensin proteins in cytotoxicity and cytolysis,
with respect to tumor immunity, is gaining more attention. Human beta defensin1 (hBD-1) is a potent "microchemokine" that attracts immature dendritic cells and
memory T cells via a specific interaction with the chemokine receptor CCR6 91 . It
is through this action that p-defensins are thought to play an important role in
both innate and adaptive immune responses, but their role in prostate tumor
progression remains unclear133 . We have previously shown that the expression
of hBD-1 is lost or suppressed in 820/0 of malignant prostate tissue, whereas
benign tissue generally expressed moderate to high levels of this peptide 134.
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Although hBD-1 expression is lost at high frequency in prostate cancer, little is
known about its function or whether this phenomenon contributes to prostate
tumor progression.
These observations led to the hypothesis that hBD-1 may have anti-tumor
activities and that its loss may contribute to prostate tumorigenesis. In this study,
we test this hypothesis by assessing the function of hBD-1 in prostate cancer.
Initial screening for hBD-1 expression revealed high levels of hBD-1 expression
in benign prostatic tissue and the prostate primary culture hPrEC. However, we
observed a loss of hBD-1 expression in adjacent malignant prostatic tissue, as
well as in DU145, PC3 and LNCaP prostate cancer cell lines. Our functional
data show that the induction of hBD-1 expression results in rapid cell death in the
late-stage prostate cancer cell lines, PC3 and DU145, but had no effect on the
early-stage prostate cancer cell line, LNCaP, or normal prostate epithelial cell
line, hPrEC, cell viability. With this, we provide the first experimental evidence
that hBD-1 may playa specific role in tumor suppression of advanced prostate
cancer. Furthermore, these data support the potential utility of hBD-1 as a
therapeutic agent for late-stage prostate cancer without cytotoxic effects to the
host.

MATERIALS AND METHODS
Cell culture
The prostate cancer cell lines were obtained from the American Type
Culture Collection (Manassas, VA) (Table 1). DU145 cells were cultured in
DMEM medium, PC3 and PC3/AR+ were grown in F12 medium, LNCaP were
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grown in RPMI medium (Life Technologies, Inc., Grand Island, NY). Growth
media for all three lines was supplemented with 10 % (v/v) fetal bovine serum
(Life Technologies). The hPrEC primary culture was obtained from Cambrex Bio
Science, Inc. (Walkersville, MD) and cells were grown in prostate epithelium
basal media (Table 1). All cell lines were maintained at 37° C and 5% CO 2 .

Tissue Samples and Laser Capture Microdissection
Prostate tissues were obtained from patients who provided informed consent
prior to undergoing radical prostatectomy. Samples were acquired through the
Hollings Cancer Center tumor bank in accordance with an Institutional Review
Board-approved protocol. This included guidelines for the processing,
sectioning, histological characterization, RNA purification and PCR amplification
of samples. Prostate specimens received from the surgeons and pathologists
were immediately frozen in OCT compound. Each OCT block was cut to produce
serial sections which were stained and examined. Areas containing benign cells,
Prostatic Intraepithelial Neoplasia (PIN), and cancer were identified and used to
guide our selection of regions from unstained slides using the Arcturus PixCell II
System (Sunnyvale, CA). Caps containing captured material were exposed to 20
IJI of lysate from the Arcturus Pica Pure RNA Isolation Kit and processed
immediately. RNA quantity and quality was evaluated using sets of primers that
produce 5' amplicons. The sets include those for the ribosomal protein L32 (the
3' amplicon and the 5' amplicon are 298 bases apart), for the glucose phosphate
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Table 1: Prostate cell lines.
Normal

hPrEC

Cancer

Site of Metastasis

DU145

Brain carcinoma

PC3

Bone adenocarcinoma

LNCaP

Left supraclavicular lymph node
carcinoma
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isomerase (391 bases apart), and for the glucose phosphate isomerase (842
bases apart). Ratios of 0.95 to 0.80 were routinely obtained for these primer sets
using samples from a variety of prepared tissues. Additional tumor and normal
samples were grossly dissected by pathologists, snap frozen in liquid nitrogen
and evaluated for hBD-1 expression.

Cloning of hBD-1 Gene

hBD-1 cDNA was generated from RNA by reverse transcription-PCR
using primers generated from the published hBD-1 sequence (Accession No.
U50930)62. The PCR primers were designed to contain Clal and Kpnl restriction
sites. hBD-1 PCR products were restriction digested with Clal and Kpnl and
ligated into a T A cloning vector. The T AlhBD-1 vector was then transfected into
the XL-1 Blue strain of E. coli by heat shock and individual clones were selected
and expanded. Plasm ids were isolated by Cell Culture DNA Midiprep (Qiagen,
Valencia, CA) and sequence integrity verified by automated sequencing. The
hBD-1 gene fragment was then ligated into the pTRE2 digested with Clal and
Kpnl, which served as an intermediate vector for orientation purposes. The

pTRE2/hBD-1 construct was digested with Apa/ and Kpnl to excise the hBD-1
insert. The insert was ligated into plND vector of the Ecdysone Inducible
Expression System (Invitrogen, Carlsbad, CA) also double digested with Apal
and Kpnl. The construct was again transfected into E. coli and individual clones
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were selected and expanded. Plasmids were isolated and sequence integrity of
plNDI hBD-1 was again verified by automated sequencing.

Transfection
Cells were seeded into appropriate dishes at least 5 hours prior to
transfection. Next, the cells were co-transfected using Lipofectamine 2000
(Invitrogen) with 2 pg/cell of pvgRXR plasmid, which expresses the heterodimeric
ecdysone receptor, and 2 pg/cell of the pIND/hBD-1 vector construct in OptiMEM media (Life Technologies, Inc.). As a control, cells were transfected with 4
pg/cell of the pvgRXR plasmid. Transfection efficiency was determined by
transfecting cells with 4 pg/cell of a pcMV-GFP vector (gift from Christina
Voelkel-Johnson laboratory, MUSC, Charleston, SC) and expressed as percent
gated following FACS analysis.

Immunocytochemistry
In order to verify hBD-1 protein expression, DU145 and hPrEC cells were
seeded onto 2-chamber culture slides (BD Falcon, USA) at 1.5-2 x 104 cells per
chamber. DU145 cells transfected with pvgRXR alone (control) or with the hBD1 plasmid were induced for 18 hours with media containing 10 lJM Pon A, while
untransfected cells received fresh growth media. Following induction, cells were
washed in 1 x PBS and fixed for 1 hour at room temperature with 4%
paraformaldehyde. Cells were then washed 6 times with 1 x PBS and blocked in
1 x PBS supplemented with 20/0 BSA, 0.8% normal goat serum (Vector
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Laboratories, Inc., Burlingame, CA) and 0.4% Triton-X 100 for 1 hour at room
temperature. Next, cells were incubated overnight in primary rabbit anti-human
BD-1 polyclonal antibody (PeproTech Inc., Rocky Hill, NJ) diluted 1 :1000 in
blocking solution. Following this, cells were washed 6 times with blocking
solution and incubated 1 hour at room temperature in Alexa Fluor 488 goat antirabbit IgG (H+L) secondary antibody at a dilution of 1:1000 in blocking solution.
After washing cells with blocking solution 6 times, coverslips were mounted with
Gel Mount (Biomeda, Foster City, CA). Finally, cells were viewed under
differential interference contrast (DIC) and under laser excitation at 488 nm. The
fluorescent signal was analyzed using a confocal microscope (Zeiss LSM 5
Pascal) and a 63x DIC oil lens with a Varia 2 RGB Laser Scanning Module. The
digital images were exported into Photoshop CS Software (Adobe Systems) for
image processing and hard copy presentation.

RNA Isolation and Quantitative RT-PCR
QRT-PCR was performed as previously described 135 . Briefly, total RNA
(0.5 J..Ig per reaction) from both sources was reverse transcribed into cDNA
utilizing random primers (Promega). Two-step QRT -PCR was performed on
cDNA generated using the MultiScribe Reverse Transcriptase from the TaqMan
Reverse Transcription System and the SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA). The primer pairs for hBD-1 and c-MYC were
generated from the published sequences (Table 2). Forty cycles of PCR were
performed under standard conditions using an annealing temperature of 56.4° C
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for hBD-1 and c-MYC. In addition, p-Actin (Table 2) was amplified as a
housekeeping gene to normalize the initial content of total cDNA. Gene
expression in benign prostate tissue samples was calculated as the expression
ratio compared to p-Actin. Relative hBD-1 expression was calculated by
comparing hBD-1 expression in malignant prostate tissue, hPREC prostate
primary culture, and prostate cancer cell lines before and after being induced for
hBD-1 expression to the average level of hBD-1 expression in benign prostate
tissue. In all cases, unless specified in the figure legend, the dissociation curves
were analyzed and matched for samples used to generate data. Specifically, the
Tm for each primer set was 77° for hBD-1 and 79° for p-Actin and cMYC. As a
negative control, QRT-PCR reactions without cDNA template were also
performed. All reactions were run a minimum of three times.

Phase Contrast Microscopic Analysis
Phase contrast microscopy was utilized to evaluate the effect of hBD-1 on
prostate cancer cells. DU145, PC3 and LNCaP cells containing no vector, empty
plasmid or hBD-1 plasmid were seeded onto 6-well culture plates (BD Falcon).
The following day plasmid-containing cells were induced for a period of 48 hours
with media containing 10 JJM Pon A, while control cells received fresh media.
The cells were then viewed under an inverted Zeiss 1M 35 microscope (Carl
Zeiss, Germany). Phase contrast pictures of a field of cells were obtained using
the SPOT Insight Mosaic 4.2 camera (Diagnostic Instruments, USA). Cells were
examined by phase contrast microscopy under 32X magnification. The digital
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Table 2: Sequences of QRT-PCR primers.
Sense (5'-3')

Antisense (5'-3')

p-actin

5'-CCTGGCACCCAGCACAAT-3'

5'-GCCGATCCACACGGAGTACT-3'

hBD-1

5'-TCAGCAGTGGAGGGCAATG-3'

5'-CCTCTGTAACAGGTGCCTTGAAT-3'

c-MYC

5'-ACAGCAAACCTCCTCACAGCC-3'

5'-TGGAGACGTGGCACCTCTTG-3'

GAPDH

5'-CCACCCATGGCAAATTCCATGGCA-3'

5'-TCTAGACGGCAGGTCAGGTCAACC-3'

AKT

5'-TCAGCCCTGGACTACCTGCA-3'

5'-GAGGTCCCGGTACACCACGT-3'

BAD

5'-CTCAGGCCTATGCAAAAAGAGGA-3'

5'-GCCCTCCCTCCAAAGGAGAC-3'

BID

5'-AACCTACGCACCTACGTGAGGAG-3'

5'-CGTTCAGTCCATCCCATTTCTG-3'
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images collected were stored as uncompressed TIFF files and exported into
Photoshop CS software (Adobe Systems) for image processing and hard copy
presentation.

MTT Cell Viability Assay

To examine the effects of hBD-1 on cell growth, we performed metabolic
3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide (MTT) assay.
DU145, LNCaP, PC3 and PC3/AR+ cells co-transfected with pvgRXR plasmid
and pIND/hBD-1 construct or control pvgRXR plasmid were seeded onto a 96well plate at 1-5 x10 3 cells per well. Twenty-four hours after seeding, fresh
growth medium was added containing 10 JJM Pon A daily to induce hBD-1
expression for 24, 48 and 72 hours after which the MTT assay was performed
according to the manufacturer's instructions (Promega). Reactions were
performed three times in triplicate.

Analysis of Membrane Integrity

Acridine orange (AO)/ethidium bromide (EtBr) dual staining was
performed to identify changes in cell membrane integrity, as well as apoptotic
cells by staining the condensed chromatin. AO stains viable cells and early
apoptotic cells, whereas EtBr stains late stage apoptotic cells that have
compromised membranes. Briefly, PC3, DU145 and LNCaP cells were seeded
into 2-chamber culture slides (BO Falcon). Cells transfected with empty plasmid
or hBD-1 plasmid were induced for 24 or 48 hours with media containing 10 tJM

48

Pon A, while control cells received fresh growth media at each time point. After
induction, cells were washed once with PBS and stained with 2 ml of a mixture
(1:1) of AO (Sigma, St. Louis, MO) and EtBr (Promega) (5

~g/ml)

solution for 5

min and were again washed with PBS.
Fluorescence was viewed by a Zeiss LSM 5 Pascal Vario 2 Laser
Scanning Confocal Microscope (Carl Zeiss). The excitation color wheel contains
BS505-530 (green) and LP560 (red) filter blocks which allowed for the separation
of emitted green light from AO into the green channel and red light from EtBr into
the red channel. The laser power output and gain control settings within each
individual experiment were identical between control and hBD-1 induced cells.
The excitation was provided by a Kr/Ar mixed gas laser at wavelengths of 543
nm for AO and 488 nm for EtBr. Slides were analyzed under 40x magnification
and the images were collected and processed as previously mentioned.

Flow Cytometry
PC3 and DU145 cells transfected with the hBD-1 expression system were
grown in 60-mm dishes and induced for 12,24, and 48 hours with 10

~M

Pon A.

Following each incubation period, the medium was collected from the plates (to
retain any detached cells) and combined with PBS used to wash the plates. The
remaining attached cells were harvested by trypsinization and combined with the
detached cells and PBS. The cells were then pelleted at 4° C (500 x g) for 5 min,
washed twice in PBS, and resuspended in 100

~I

of 1xAnnexin binding buffer

(0.1 M Hepes/NaOH at pH 7.4, 1.4 M NaCI, 25 mM CaCb) containing 5
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~I

of

Annexin V-FITC and 5 IJI of PI. The cells were incubated at RT for 15 m in in the
dark, then diluted with 400 IJI of 1x Annexin binding buffer and analyzed by
FACscan (Becton Dickinson, San Jose, CAl. All reactions were performed three
times.

Caspase Detection
Detection of caspase activity in the prostate cancer cell lines was
performed using APO LOGIX™ Carboxyfluorescin Caspase detection kit (Cell
Technology, Mountain View, CAl. Active caspases were detected through the
use of carboxyfluorescein labeled peptide fluoromethyl ketone (FAM-VAD-FMK)
that irreversibly binds to active caspases. Briefly, DU145 and LNCaP cells (1.5-3
X10

5
)

containing the hBD-1 expression system were plated in 35 mm glass

bottom dishes (Matek, Ashland, MA) and treated for 24 hours with media only or
with media containing 10 IJM Pon A as previously described. Next, 10 IJI of a
30X working dilution of FAM-VAD-FMK was added to 300 IJI of media and added
to each 35 mm dish. Cells were then incubated for 1 hour at 37° C under 50/0
CO 2 . The medium was aspirated and the cells were washed twice with 2 ml of a
1x working dilution Wash Buffer. Cells were viewed under differential
interference contrast (OIC) or under laser excitation at 488 nm. The fluorescent
signal was analyzed using a confocal microscope (Zeiss LSM 5 Pascal) and a
63x DIG oil lens with a Vario 2 RGB Laser Scanning Module.
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Statistical Analysis
Statistical analysis was performed by using the Student's t-test for
unpaired values. P values were determined by a two-sided calculation, and a P
value of less than 0.05 was considered statistically significant. Statistical
differences are indicated by asterisks.

RESULTS
hBO-1 Expression in Prostate Tissue
We previously demonstrated that 820/0 of prostate cancer frozen tissue
sections analyzed exhibited little or no expression of hBD-1 136 . In addition, in
that study we observed a potential correlation between clinical prostate samples
with little or no expression of hBD-1 and higher rates of cancer recurrence
(unpublished data). To compare hBO-1 expression levels, QRT-peR analysis
was performed on normal prostate tissue obtained by gross dissection or LCM of
normal prostate tissue adjacent to malignant regions which were randomly
chosen. Here, hBD-1 was detected in all of the gross dissected normal clinical
samples with range of expression that represents approximately a 6.6-fold
difference in expression level (Figure 3-1A). LCM captured normal samples
expressed hBD-1 at levels in a range that represents a 32-fold difference in
expression (Figure 3-1 B). Matching sample numbers to corresponding patient
profiles revealed that in most cases, the hBD-1 expression levels was higher in
patient samples with a Gleason score of 6 than in patient samples that had a
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Figure 3-1: Analysis of hBD-1 expression in human prostate tissue. hBD-1
relative expression levels were compared in normal clinical samples from
patients that underwent radical prostatectomies. The dashed line serves as a
point of reference to compare values obtained between gross and LCM-derived
specimen, and corresponding Gleason scores are indicated above each bar. (A)
hBD-1 expression levels were compared in tissues obtained by gross dissection.
(8) hBD-1 expression levels were compared in tissue obtained by Laser Capture
Microdissection.
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Figure 3-1: Analysis of hBD-1 expression in human prostate tissue.
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Gleason score of 7. In addition, a comparison of hBD-1 expression levels in
tissue obtained by gross dissection and LCM for the same patient, #1343,
demonstrated an 854-fold difference in expression between the two isolation
techniques. Therefore, our results indicate LCM is a more sensitive technique to
assess hBD-1 expression in prostate tissue.

Transfection Efficiency in Prosate Cancer Cell Lines
To determine the transfection efficiency, the prostate cancer cell lines
were transfected with a GFP vector and fluorescence was monitored.
Microscopic analysis revealed green fluorescence in only the prostate cancer cell
lines transfected with GFP (Figure 3-2). In addition, the flow analysis of GFP
positive cells demonstrated an approximate 50% transfection efficiency in all
three prostate cancer cell lines.

hBO-1 Expression in Prostate Cell Lines
To verify upregulation of hBD-1 in the prostate cancer cell lines after
transfection with the hBD-1 expression system, QRT -PCR was performed. In
addition, no template negative controls were also performed, and amplification
products were verified by gel electrophoresis (Figure 3-3). Here, hBD-1
expression was significantly lower in the prostate cancer cell lines compared to
hPrEC cells. Following a 24 hour induction period, relative expression levels of
54

Figure 3-2: Analysis of Transfection Efficiency with GFP Plasmid. (A)
Microscopic analysis of GFP transfection efficiency. (8) Graph representing the
percent gated during flow analysis for GFP.
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Figure 3-3: Analysis of peR products. (A) RT-PCR was performed in DU145
and PC3 after induction for hBD-1 expression. (B) Products were verified by gel
electrophoresis.
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Induced

Figure 3-4: Analysis of hBD-1 expression in prostate cell lines. hBD-1
expression levels were compared relative to hPrEC cells in prostate cancer cell
lines before and after hBD-1 induction. An asterisk represents statistically higher
expression levels compared to hPrEC. Double asterisks represent statistically
significant levels of expression compared to the cell line before hBD-1 induction
(Student's t-test, p < 0.05).

10000
**

1000

r::

o

-(ii ~

**

100

**

(/J

[~
)(

't-

UJ

0

CD >
CI)

.>
...,
CI.)

-IX:ca
G)

10
1

0. . 1

..J

0 .01

0.001
hPrEC

DU145

DU145
hBO-1

LNCaP LNCaP
hBO-1

PC3

Figure 3-4: Analysis of hBD-1 expression in prostate cell lines.

60

PC3
hBD-1

hBO-1 significantly increased in DU145, PC3 and LNCaP as compared to the cell
line prior to hBD-1 induction (Figure 3-4).

Analysis of hBD-1 relative expression

in the prostate cancer cell lines revealed that we can induce hBD-1 in prostate
cancer cells as compared to endogenous hBD-1 expression in normal prostate
cells.
Next, we verified protein expression of hBD-1 in DU145 cells transfected
with the hBD-1 expression system after induction with Pon A utilizing
immunocytochemistry. As a positive control, hBD-1 expressing hPrEC prostate
epithelial cells were also examined. Cells were stained with primary antibody
against hBD-1 and protein expression was monitored based on the green
fluorescence of the secondary antibody (Figure 3-5). Analysis of cells under DIG
verifies the presence of hPrEC cells and DU 145 cells at 18 hours.

Excitation by

the confocal laser at 488 nm revealed green fluorescence indicating the
presence of hBD-1 protein in hPrEC. However, there was no detectable green
fluorescence in control DU145 and pvgRXR induced DU145 cells demonstrating
no hBD-1 expression (d and f, respectively). Confocal analysis of DU145 (h)
cells induced for hBD-1 expression revealed green fluorescence indicating the
presence of hBD-1 protein following induction with Pon A.

Expression of hBD-1 Results in Decreased Cell Number and Viability

To test the effect of hBD-1 on prostate cancer cell lines, we perfonned
phase contrast microscopic analysis of prostate cancer cell lines. Induction of
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Figure 3·5: Analysis of hBO-1 protein expression. Ectopic hBD-1 expression
was verified in the prostate cancer cell line DU145 by immunocytochemistry.
hPrEC cells were stained for hBD-1 as a positive control (a: DIG and b:
fluorescence). DU145 control cells (c: DIG and d: fluorescence) or DU145 cells
transfected with pvgRXR alone (e: DIG and f: fluorescence) or hBD-1 and
induced for 18 h (g: DIC and h: fluorescence). Size bar =20pM.
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Figure 3-5: Analysis of hBD-1 protein expression.
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hBD-1 in the prostate cancer cell lines resulted in a significant reduction in cell
number in DU145 and PC3, but had no effect on cell proliferation in LNCaP
(Figure 3-5). As a negative control, cell growth was monitored in all three lines
after the induction of the pvgRXR vector. There were no observable changes in
cell number in DU145, PC3 or LNCaP cells.
We performed an MTT assay to assess the effect of hBD-1 expression on
relative cell viability in DU145, PC3, PC3/AR+ and LNCaP prostate cancer cell
lines. MTT analysis with pvgRXR vector exhibited no statistically significant
change in cell viability (data not shown). Twenty-four hours following hBD-1
induction, relative cell viability was 72% in DU145 and 56% in PC3, and after 48
hours cell viability was reduced to 49% in DU145 and 370/0 in PC3 (Figure 3-7).
Following 72 hours of hBD-1 induction, relative cell viability decreased to 44% in
DU145 and 29% PC3 cells. Conversely, there was no significant effect on the
viability of LNCaP cells. In order to assess whether the resistance to hBD-1
cytotoxicity observed in LNCaP was due to the presence of the androgen
receptor (AR), we examined the hBD-1 cytotoxicity in PC3 cells with ecpotic AR
expression (PC3/AR+). Here, there was no difference between PC3/AR+ and
PC3 cells. Therefore, the data suggest that hBD-1 is cytotoxic specifically to
late-stage prostate cancer cells.
In order to determine whether the effects of hBD-1 on PC3 and DU145
were cytostatic or cytotoxic, FACS analysis was performed to measure cell
death. Under normal growth conditions, more than 90% of PC3 and DU145
cultures were viable and non-apoptotic (lower left quadrant) that did not stain with
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Figure 3·6: Analysis of hBO-1 on prostate cancer cells. Cell number in
DU145, PC3 and LNCaP was monitored by phase contrast microscopy after 48
hours of hBD-1 induction. Size bar= 20 IJM.

Control

pvgRXR

hBD-1

DU145

PC3

LNCaP

Figure 3-6: Analysis of hBO-1 on prostate cancer cells.
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Figure 3-7: Analysis of hBD-1 effect on cell viability. The prostate cell lines
DU145, PC3, PC3/AR+ and LNCaP were treated with Pon A to induce hBD-1
expression for 1-3 days after which MTT assay was performed to determine cell
viability. Each bar represents the mean + S.E.M. of three independent
experiments performed in triplicate.
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annexin V or PI (Figure 3-8). After inducing hBD-1 expression in PC3 cells, the
number of cells undergoing early apoptosis and late apoptosis/necrosis (lower
and upper right quadrants, respectively) totaled 10 % at 12 hours, 200/0 at 24
hours, and 44% at 48 hours. For DU145 cells, the number of cells undergoing
early apoptosis and late apoptosis/necrosis totaled 12% after 12 hours, 34% at
24 hours, and 59% after 48 hours of induction. No increase in apoptosis was
observed in cells containing empty plasmid following induction with Pon A (data
not shown). Annexin V and propidium iodide uptake studies have demonstrated
that hBD-1 has cytotoxic activity against DU145 and PC3 prostate cancer cells
and results indicate apoptosis as a mechanism of cell death.

hBO-1 Causes Alterations in Membrane Integrity and Caspase Activation

We investigated whether the cell death observed in prostate cancer cells
after hBD-1 induction is caspase-mediated apoptosis. To better understand the
cellular mechanisms involved in hBD-1 expression, confocal laser microscopic
analysis was performed (Figure 3-9) on DU145, PC3, and LNCaP cells induced
for hBD-1 expression. Pan-caspase activation was monitored based on the
binding and cleavage of green fluorescing FAM-VAO-FMK to caspases in cells
actively undergoing apoptosis. Analysis of cells under DIC showed the presence
of viable control DU145 (a), PC3 (e), and LNCaP (i) cells at 0 hours. Excitation
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Figure 3-8: Analysis of hBD-1 cytotoxicity in prostate cancer cells. Cells
positive for propidium iodide and annexin V were considered apoptotic. Times of
induction are shown under each panel. Numbers next to the boxes for each time
point represent the percentages of propidium iodide (PI)- annexin V+ cells (lower
right quadrant), and PI+ annexin V+ cells (upper right quadrant).
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Figure 3-9: Analysis of pan-caspase activation. Analysis of hBD-1 mediated

cell death in OU145, PC3, and LNCaP prostate cancer cells. OIC visualization of
cells before (a, e, and I, respectively) and after (c, g, and k, respectively) hBO-1
induction. Fluorescence analysis revealed no caspase activity in control cells (b,
f, and j, respectively), however, cells treated with Pon A for 24 h to induce hBO-1
revealed caspase activity in DU145 and PC3 (d and h respectively), but not in
LNCaP (I).
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Figure 3-9: Analysis of pan-caspase activation.
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by the confocal laser at 488 nm produced no detectable green staining which
suggests no caspase activity in DU145 (b), PC3 (f), or LNCaP (j) control cells.
Following induction for 24 hours, DU145 (c.), PC3 (g.), and LNCaP (h.)
cells were again visible under DIG. Confocal analysis under fluorescence
revealed green staining in DU145 (d.) and PC3 (h.) cells indicating pan-caspase
activity after the induction of hBD-1 expression. However, there was no green
staining in LNCaP (I.) cells induced for hBD-1 expression. Therefore, cell death
observed following induction of hBD-1 is caspase-mediated apoptosis.
The proposed mechanism of antimicrobial activity of defensin peptides is
the disruption of the microbial membrane due to pore formation

33,64.

In order to

determine if hBD-1 expression altered membrane integrity EtBr uptake was
examined by confocal analysis (Figure 3-10). Intact cells were stained green due
to AD which is membrane permeable, while only cells with compromised plasma
membranes stained red due to incorporation of membrane impenneable EtBr.
Control DU145 and PC3 cells stained positively with AD and emitted green color,
but did not stain with EtBr. Howev~r, hBD-1 induction in both DU145 and PC3
resulted in the accumulation of EtBr in the cytoplasm at 24 hours as indicated by
the red staining. By 48 hours, DU145 and PC3 possessed condensed nuclei and
appeared yellow due to the co-localization of green and red staining from AO and
EtBr, respectively. Conversely, there were no observable alterations to
membrane integrity in LNCaP cells after 48 hours of induction as indicated by
positive green fluorescence with AD, but lack of red
EtBr fluorescence. This
...
~

finding suggests that alterations to membrane integrity and permeabilization in
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Figure 3-10: Analysis of membrane integrity. Membrane integrity of DU145,
PC3 and LNCaP was analyzed by confocal microscopy 24 and 48 h after hBD-1
induction. Green staining indicates the localization of AD, red staining represents
EtBr and yellow staining represents the co-localization of both AO and EtBr. Size
bars

=10 pM.
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Figure 3-10: Analysis of membrane integrity.
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response to hBO-1 expression differ between early- and late-stage prostate
cancer cells.

hBD-1 Expression Correlates with cMYC and PAX2

QRT-peR analysis was performed on LCM prostate tissue sections from
three patients.

Here, hBD-1 expression exhibited a 2.7-fold decrease from

normal to PIN, a 3.5-fold decrease from PIN to tumor and a 9.3-fold decrease
from normal to tumor in patient # 1457 (Figure 3-11). Likewise, we observed
cMYC expression followed a similar expression pattern in patient # 1457 where
expression decreased by 1.7-fold from normal to PIN, 1.7-fold from PIN to tumor
and 2.8-fold from normal to tumor. In addition, we saw a statistically significant
decrease in cMYC expression in the other two patients. Patient # 1569 had a
2.3-fold decrease from normal to PIN, while in patient # 1586 we saw a 1.8-fold
decrease from normal to PIN, a 4.3-fold decrease from PIN to tumor and a 7.9fold decrease from normal to tumor. Conversely, PAX2 expression increased
from normal to malignant tissue by 6.6-fold in patient # 1586. Although we did
not observe a direct correlation of hBD-1 and PAX2 expression, our results
indicate that both PAX2 and cMYC expression may influence hBO-1 levels.
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Figure 3-11: QRT-peR analysis of hBD-1 and cMYC expression in LCM
human prostate tissue sections of normal, PIN, and tumor . Expression for
each gene is presented as expression ratios compared to p-actin. (A)
Comparison of hBO-1 expression levels in normal, PIN and tumor sections. (8)
Comparison of cMYC expression level in normal, PIN and tumor sections.
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79

Induction of hBO-1 Expression Following PAX2 Inhibition

To further examine the role of PAX2 in regulating hBD-1 expression, we
utilized siRNA to knockdown PAX2 expression and performed QRT-peR to
monitor hBD-1 expression. Treatment of hPrEC cells with PAX2 siRNA exhibited
no effect on hBD-1 expression (Figure 3-12). However, PAX2 knockdown
resulted in a 42-fold increase in LNCaP, a 37-fold increase in PC3 and a 1026fold increase in DU145 expression of hBD-1. As a negative control, cells were
treated with non-specific siRNA which had no significant effect on hBD-1
expression (data not shown).

DISCUSSION

The identification of susceptibility genes and genetic alterations
associated with prostate cancer has greatly enhanced our understanding of the
disease

65.

However, the basic mechanism underlying prostate carcinogenesis is

still poorly understood. Recent interest has focused on the role inflammation or
infection in the progression of prostate cancer 65-67. Members of the defensin
family of peptides have an important role in host defense against bacterial fungal
j

and viral infections 68 and are considered a critical part of the initial response to a
pathogen

35.

In contrast to other members of the defensin family, hBD-1 exhibits

no activity against fungal and viral infections and only very weak antimicrobial
activity. Given this, the exact role of hBD-1 expression in the epithelial cell
remains unclear 69-71.
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Figure 3-12: QRT-PCR analysis of hBD1 expression following PAX2
knockdown with siRNA. hBO-1 expression levels are presented as expression
ratios compared to p-actin. An asterisk represents statistically higher expression
levels compared to the cell line before PAX2 siRNA treatment (Student's t-test,

p < 0.05).

0.1

-' .00

Q.OOCO:l1

l::JlCaP
C,_ ,II Line

_,L,, 4 5

.f

Figure 3-12: QRT-PCR analysis of hBD1 expression following PAX2
knockdown with siRNA.
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Our previous studies have shown that hBD-1 expression is lost at a high
frequency in prostate cancer2°. However, little is known about its function in
cancer or whether the loss of expression contributes to prostate tumor
progression. There has been increasing interest in whether host defense
peptides possess anti-cancer activi ty137. Here we show that hBO-1 is cytotoxic to
prostate cancer cells. Overall, hBD-1 expression was 10- to almost 1ODD-fold
less in grossly dissected tissues compared to LCM tissue samples. Furthermore,
expression in benign prostate tissue adjacent to cancer varied over a range
differing by 6.6-fold difference in gross dissected tissues and a 32-fold difference
in LCM derived tissue. In this, we found that patient #1343 had an 854-fold
difference in detectable hBD-1 expression when comparing gross and LCM
derived tissue. The increase in detectable levels of hBD-1 from gross to LCM
derived tissue indicates LCM is a more sensitive technique to analyze expression
of hBO-1. Additionally analysis indicated that in most cases, patient samples
with higher hBD-1 expression levels had a Gleason score of 6, while those with
less expression were diagnosed with cancers having Gleason score of 7.
Although LCM derived tissue appeared to display the trend of higher hBD-1
expression and lower Gleason score, other factors such as degree of
inflammation within the tissue were not evaluated in this study. In addition, we
have preliminary data from a previous long-term patient follow-up which suggests
that those with little to no hBD1 expression experienced higher cancer
recurrence rates compared to those with higher expression levels. Taken
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together, these results suggest that decreased or loss of hBD-1 expression and
its subsequent anti-cancer activity may contribute to prostate tumor progression.
In 2006, Sherman et al. published data indicating that hBD-1 is
upregulated in response to BSA treatment and the pathway involved may be
regulated by the c-Myc proto-oncogene 137 , 138. C-myc has also been shown to
sensitize tumor cells to various apoptotic stimuli 139 . One of these pathways
involves the permeabilization of the cellular and mitochondrial membranes, and
the release of cytochrome C. Therefore, c-Myc must act to potentiate the ability
of an additional factor to induce permeabilization and cytochrome C release.
However, in cancer cells c-Myc-induced release of cytochrome C is suppressed
by cell survival factors, which subsequently exacerbates c-Myc oncogenicity.
Given that all potential pro-apoptotic actions of c-Myc involve its
functional integrity as a transcription factor, it is possible that c-Myc modulates
target genes that encode proteins which can permeabilize the mitochondrial
membrane. Here we show that hBD-1 causes rapid cell death in late-stage
prostate cancer cells via the disruption of cell membrane potential and caspase
activation. Furthermore, we found!"a positive correlation between cMyc and hBO1 in one of three prostate tissue samples, where tissue exhibiting decreased
cMyc expression also possessed a decreased hBO-1 level. This suggests that
the loss of hBD1 observed in prostate cancer may be due to the down-regulation
of cMyc expression or by the up-regulation of transcription factors acting as prosurvival factors, therefore preventing the triggering of apoptosis, and ultimately
promoting tumor progression.
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Paired box 2, PAX2, is a member of the PAX gene family of transcriptional
regulators that functions early in the development of the urogenital system 140.
Although PAX2 is typically repressed upon terminal differentiation, in urogenital
cancers including prostate cancer it has been shown to be overexpressed 141 , 142.
In addition, studies have demonstrated that PAX2 expression can stimulate
proliferation stimulus, thus serving as a critical component of a multi-step
oncogenic transformation process 143. Therefore, PAX2 may offer an advantage
for the survival and growth of cancer cells.
PAX genes function to activate or repress transcription by transactivating
the promoters of target genes that regulate cell growth and apoptosis 144. Unique
recognition sequences are contained within the paired domain and activating
domains in PAX2 that aid to activate or repress the transcription of specific
genes145, 146. Examination of the hBD-1 promoter revealed a PAX2 recognition
sequence between bases-172 and -157 upstream of the TAT A box (data not
shown). Here we demonstrate a 6.6-fold increase from normal to tumor in PAX2
expression in patient # 1586. Although we did not observe a direct correlation
with hBD-1 and PAX2 expression in the patient samples tested, we did
demonstrate that suppression of PAX2 protein expression by siRNA results in the
re-expression of hBD1. These findings suggest that PAX2 is a transcriptional
repressor of hBD-1 expression although this was not examined in this study.
Taken together, it is plausible that the delicate balance of the regulation of hBD-1
expression may playa key role in determining the fate of cancer cells and tumor
progression.
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In summary, data presented here demonstrate that hBO-1 expression is
highly cytotoxic to DU145 and PC3 which represent AR negative, hormone
refractory late-stage prostate cancer. These findings suggest that hBO-1 has
anti-cancer and/or tumor suppressive activities and that its suppression or loss
contributes to cancer cell survival and tumor progression. Cytotoxic effects of
hBO-1 observed in DU145 and PC3, but not in LNCaP suggest that hBO-1
specifically affects late-stage prostate cancer cells. This reasoning is further
supported by the high frequency of cancer-specific loss of hBD-1 expression, and
that hBD-1 loss of expression may influence Gleason grading and cancer
recurrence. Therefore, hBD-1 may be an integral component of the innate
immune system involved in the recognition and destruction of cancer cells. In
conclusion, our studies are the first to demonstrate hBO-1 functionality in
prostate cancer progression, thus offering hBO-1 as a viable therapeutic agent
for the treatment of late-stage prostate cancer.
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CHAPTER 4
CELLULAR MECHANISMS ASSOCIATED WITH THE
EFFECTS OF HBD-1 ON PROSTATE CANCER CELLS

•.

...._.
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INTRODUCTION

Apoptosis is a mechanistic process whereby the activation of cysteineaspartate proteases (caspases) results in programmed cell death that allows
multicellular organisms to regulate cell number within tissues. It is characterized
by stereotypical morphological changes, such as chromatin condensation and
fragmentation, cell shrinkage, and alterations of the plasma membrane. In part,
apoptosis is regulated by the Bcl-2 fam ily of proteins 147. There are two pathways
of apoptosis, an extrinsic pathway involving ligand activated cell death receptors
and an intrinsic pathway involving mitochondrial alterations initiated by a variety
of stress signals141. The extrinsic pathway involves the recruitment of adapter
proteins that lead to the activation of caspase 8 and the initiation of the caspase
cascade. Activated caspase 8 catalyzes the cleavage of BID leading to the
translocation of tBID to the mitochondria and subsequent cell death. In the
intrinsic pathway, the release of cytochrome c from the mitochondria, in
conjunction with APAF-1, results in the formation of the apoptosome. This aids
in the cleavage of procaspase-9 inJhe presence of ATP generating an active
caspase 9, which, in turn, activates the effector caspases. The extrinsic and
intrinsic pathways merge at caspase 3 activation to complete the apoptotic
process. Ultimately, the process results in the morphological and biochemical
changes characteristic of apoptotic death.
Apoptosis is an important and physiologically normal course of action for
multicellular organisms148 . It is accepted that th~_growth and progression of a
tumor is regulated by deregulation of the balance between proliferation and
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apoptosis 149,150. The ability of a cell to evade apoptosis is an important
characteristic that defines the transition from a normal cell to malignant151 .
Further study into the molecular mechanisms underlying the process could lead
to the development of possible preventative strategies.
In prostate cancer, mortality is a consequence of metastasis to the lymph
nodes and bone, as well as a progression from androgen-dependent to
androgen-independent growth 152. There are limited treatment options beyond
localized prostate cancer due to the ineffective nature of chemotherapy to
increase patient survival in metastatic prostate cancer 153 . Although the
accumulation of genetic alterations and environmental insults contributes to the
development and progression of prostate cancer, the exact molecular
mechanisms underlying these processes are unknown. An important
pathophysiological response that appears to contribute to prostate cancer
involves the inhibition of apoptosis. Therefore, identification of potential
therapeutic targets that manipulate the apoptotic process may serve as
alternative treatment methods leading to a decrease in prostate cancer mortality
rates.

MATERIALS AND METHODS
Specific Caspase Activity
Specific caspase activity in the prostate cancer cell lines was detected
using the Carboxyfluorescein or Sulforhodamine FLICA Apoptosis Detection Kit
Caspase Assay (Immunochemistry Technologies~-·LLC, Bloomington, MN).
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Caspase 8 was detected with a FAM-LETO-FMK peptide, caspase 9 with a FAMLEHO-FMK peptide, and caspases 3 & 7 with a SR-OEVO-FMK peptide that
irreversibly binds to active caspases. Briefly, 1.5-3x1 0 5 DU 145, LNCaP and PC3
cells were plated on 35-mm glass bottom dishes (MATEK, Ashland, MA) and
were transfected with the hBD-1 expression system. As previously described,
cells were exposed to media only or media containing Pon A for 24-48 hours.
Next, 10 ul of a 30X working dilution of the appropriate fluoromethyl ketone
labeled peptide was added to 300 ul of media and incubated with each 35-mm
dish for 1 hour at 37°e under 5% CO 2 _ Then, the medium was aspirated and the
cells were washed twice with 2 ml of 1X working dilution Wash buffer. Cells were
viewed under differential interference contrast (Ole) or laser excitation at 488
nm. The fluorescent signal and DIC images were analyzed using a confocal
microscope (Zeiss LSM 5 Pascal) and 63X oil lens with a Vario 2 RGB Laser
Scanning Module. Images were collected and processed as previously
mentioned.

RNA Isolation and Quantitative RT-PCR
QRT-peR was performed as previously described 135 . Briefly, total RNA
(O.5 1-19 per reaction) from both sources was reverse transcribed into eDNA

utilizing random primers (Promega). Two-step QRT -peR was performed on
eDNA generated using the MultiScribe Reverse Transcriptase from the TaqMan
Reverse Transcription System and the SYBR Green peR Master Mix (Applied
Biosystems, Foster City, CA). The primer pairs for AKT, BAD, and BID were
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designed from the published sequences (Table 2). Forty cycles of peR were
performed under standard conditions using an annealing temperature of 58° C.
In addition, GAPDH (Table 2) was amplified as a housekeeping gene to
normalize the initial content of total cDNA. Gene expression in benign prostate
tissue samples was calculated as the expression ratio compared to GAPDH.
Relative expression was calculated by comparing mRNA levels in prostate
cancer cell lines after being induced for hBD-1 expression to the level of mRNA
expression in control cells. In all cases, the dissociation curves were analyzed
and matched for samples used to generate data. As a negative control, QRTpeR reactions without cDNA template were also performed. All reactions were
run a minimum of three times.

Western Blot Analysis
Protein levels were analyzed by western blot analysis. Briefly, 5-7.5 x10 5
cells were plated on 100mm dishes and transfected with the appropriate amount
of pvgRXR vector or pIND/hBD-1 plasmid. Lysates were collected following 20h
of induction with Pan A. Samples were prepared for a triple load: 75 pi sample,
15 pi sample buffer, and 1.5 pl1 M OTT. After incubation at 70 0 e for 10 min, the
samples were loaded onto a 4-12% NuPAGE gel and run for 50 min at 200V with
MES running buffer containing anti-oxidant (Invitrogen). Transfer was perfonned
at 30V for 1 hr (one gel/power supply) or 1.5 hrs (two gels/power supply). The
nitrocellulose was blocked in 5% milk in T8S-T for a minimum of 30 min at RT.
Incubation O/N at 4°C in 5% milkrrBS-T with a primary antibody concentration of
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1:1000 for anti-caspase 3, anti-caspase 8, anti-caspase 9, Bid, Bad, AKT, pAKT,
and p-actin (Cell Signaling, Beverly, MA) was followed with 3x10 min washes
with TBS-T. Then, the blots were incubated for 1-2 hrs at RT in 5% milk-TBS-T
with secondary antibody (1 :5000 mouse, 1:50000 rabbit), washed 3x10 min T8ST and incubated with chemiluminescent reagent prior to development.

RESULTS
hBD-1 Causes Caspase Activation

We have shown that the induction of hBD-1 expression in DU145 and PC3
prostate cancer cell lines results in the activation of caspases, while there are no
active caspases observed in LNCaP. To better understand the molecular
mechanisms involved in caspase-mediated cell death, confocal microscopic
analysis was performed. In order to delineate the apoptotic response in cells
induced for hBO-1 expression, caspase 8 from the extrinsic pathway, caspase 9
for the intrinsic pathway and caspase 3 where the two pathways converge were
monitored with a FAM-FLICA or SR-FLICA kit that reacts with the active caspase
within minutes.
Analysis of caspase 8 activation with FAM-LETO-FMK, a fluorescent
green probe, demonstrated no detectable staining in DU145, PC3 or LNCaP
control cells (Figure4-1). However, confocal analysis of DU145 and PC3 cells
induced for hBO-1 expression revealed green staining indicative of caspase 8
activation. Similarly, specific activation of caspase 9 was monitored with FAM-
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Figure 4-1: Analysis of caspase 8 activation. Fluorescence analysis revealed
no caspase activation in DU145, PC3, or LNCaP control cells. However, caspase
8 activation was observed in DU145 and PC3 induced for hBD-1 expression.

PC3

DU145

Control

Induced

Figure 4-1: Analysis of caspase 8 activation.
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LNCaP

LEHD-FMK, a green fluorescent probe. Again, the analysis of control cells
produced no detectable green fluorescence, while DU145 and PC3 cells induced
for hBD-1 expression revealed the green fluorescence indicating the presence of
active caspase 9 (Figure 4-2). The activation of caspase 3 was monitored with
SR-DEVD-FMK, a fluorescent red probe, in DU145, PC3 and LNCaP prostate
cancer cell lines. There was no detectable staining in control cells, however, red
fluorescence was observed in DU145 and pe3 cells following induction for the
expression of hBD-1 (Figure 4-3). Therefore, the cell death observed following
induction of hBD-1 is caspase-mediated apoptosis which involves both the
intrinsic and extrinsic pathways converging at caspase 3, the effector caspase.
To verify the fluorescence data, we monitored the protein levels of
caspases 3,8, and 9 in DU145 cells before and after induction. Cells induced for
the expression of the pvgRXR vector or hBD-1 plasm id for 24hrs were analyzed
by western blot (Figure 4-4). There was not a significant decrease from control in
the cells induced for pvgRXR in procaspases 3, 8, and 9. However, a reduction
in procaspases 3, 8, and 9 was observed in cells induced for hBD-1 expression.
Additionally, the fragments that result from the cleavage of procaspase 3 and 9
into the active forms were shown. ImageJ analysis verified the decrease in
procaspase 3,8, and 9 levels observed by western blot (data not shown).
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Figure 4... 2: Analysis of caspase 9 activation. Fluorescence analysis revealed

no caspase activation in DU145, PC3, or LNCaP control cells. However, caspase
9 activation was observed in DU145 and PC3 induced for hBD-1 expression.

pe3

DU145

Control

Induced

Figure 4-2: Analysis of caspase 9 activation.
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LNCaP

Figure 4-3: Analysis of caspase 3 activation. Fluorescence analysis revealed
no caspase activation in DU145, PC3, or LNCaP control cells. However, caspase
3 activation was observed in DU145 and PC3 induced for hBO-1 expression.
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DU145
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Induced

Figure 4-3: Analysis of caspase 3 activation.
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LNCaP

Figure 4-4: Western blot analysis of caspase activation. Protein from DU145

cells was collected to perform a western blot analysis following induction for hBO-

1 expression.

Control

pvgRXR hBD-1

Procaspase 3

Caspase 3 Cleavage
Products

Procaspase 8

Procaspase 9

Actin

Figure 4-4: Western blot analysis of caspase activation.
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Regulators of Apoptosis following hBD-1 expression
Several regulators of apoptosis are important to the activation or
suppression of cell death. Akt, an important pro-survival kinase, is involved in
protecting cells from apoptosis. Stimulation with growth factors leads to Akt
recruitment to the plasma membrane and phosphorylation at two key regulatory
sites, Thr308 and Ser473 , by 3-phosphoinositide-dependent protein kinase-1
(PDK1 )154. Analysis of the effect of hBD-1 expression on Akt mRNA levels
revealed a decrease in DU145 and no change in PC3, while protein analysis in
DU145 demonstrated no change in Akt levels and a slight decrease in pAkt
(Figure 4-5).
One important substrate of Akt is Bad, a BH3-domain protein which if
phosphorylated becomes sequestered to the cytoplasm and prevents it from
translocating to the mitochondrion where it exerts its pro-apoptotic action 155. An
increase in Bad mRNA levels was observed in both DU145 and PC3 following
the induction of hBD-1 (Figure 4-6). Subsequent analysis of Bad protein levels
demonstrated a decrease in hBO-1 induced cells from those of control DU145.
At first, the observed decrease in Bad protein levels suggests that there is less

apoptosis. However, it is important to note that the RNA and protein isolates
were collected at the 24h time pOint. Since an increase in transcript levels was
observed, additional later time points may have demonstrated the expected
increase in Bad protein levels.
The final pro-apoptotic factor that was analyzed, Bid, is cleaved by
activated caspase 8 into a truncated BH-3 only domain form known as tBid. It

102

Figure 4-5: Effect of hBD-1 on Akt and pAkt expression. (A) Akt m RNA

expression in DU145 and PC3 before and after induction for hBD-1 expression.
(8) Akt protein expression in DU145. (C) pAkt protein expression in DU145.
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Figure 4-5: Effect of hBO-1 on AKT
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and pAKT expression.

Figure 4-6: Effect of hBD-1 on Bad expression. (A) mRNA expression in
DU145 and pe3 before and after induction for hBD-1 expression. (8) Protein
expression in DU145: lane 1-control cells, lane 2- cells induced for pvgRXR
vector expression, lane 3- cells induced for hBO-1 expression.
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Figure 4-7: Effect of hBD-1 on Bid expression. (A) mRNA expression in
DU145 and PC3 before and after induction for hBD-1 expression. (8) Protein
expression in DU145: lane 1-control cells, lane 2- cells induced for pvgRXR
vector expression, lane 3- cells induced for hBD-1 expression.
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results were evidenced by a decrease in cell number and the appearance of
cleaved caspase 8 and 9 fragments 57 . Furthermore, in mice it has been shown
the over-expression of mouse p-defensin-6 results in myofiber apoptosis 159.
In summary, data presented here support the recent findings that
demonstrate hBO-1 expression is highly cytotoxic in human prostate cancer cells.
Specifically, we have shown that the death observed in DU145 and PC3 prostate
cancer cells involves the activation of caspases 3,8 and 9. In addition, there
were alterations in the expression pattern of various regulators of apoptosis. We
are confidant the induced cell death is due to hBO-1 expression because
appropriate vector controls were used in each experiment. These findings
suggest that hBD-1 has anti-cancer activities via an apoptotic cell death. Taken
together, it is plausible that hBO-1 expression within the tumor microenvironment
may playa key role in determining the fate of cancer cells and tumor
progression. However, the mechanisms and receptors, if any, involved in the
pro-apoptotic response of hBO-1 remain unclear and require additional studies.
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CHAPTER 5
ROLE OF HBO-1 IN PROSTATE CANCER PROGRESSION
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INTRODUCTION

One philosophy for the successful treatment of cancer involves
eradicating all of the tumor cells from the body. Conventional modalities to
eliminate cancer cells include surgical removal of the tumor mass, radiotherapy
and chemotherapy which use exposure to toxic ionizing radiation and chemicals,
respectively, to destroy tumor cells. Although these methods are regularly used
to treat cancer, they have associated limitations and side effects.
There are two significant limitations connected with the use of radio- or
chema-therapy. First, there is an observed toxicity to both malignant cells and
their normal counterparts rapidly dividing within the treatment field. Second,
there is significant data that shows the development of drug resistance within a
subset of malignant cells following treatment. In an effort to circumvent these
limitations, research has been conducted to identify new modalities without the
side effects to the host.
One particular area of interest involves the phenomena termed bystander
..

effect. Typically, the term bystander effect is used in radiobiology to describe the
effects of radiation on cells adjacent to those directly affected by radiation.
However, it has recently been adapted more generally to refer to the effect a
particular treatment of cells has on those that have not received any treatment.
The work presented here was designed to test our hypothesis that hBD-1
exhibits a bystander effect. In this study, we testihis hypothesis by assessing
the effect of hBD-1 containing media on prostate cancer cell lines. Although we
1 12

do not observe a bystander effect in our studies, our results indicate a possible
upward trend. This suggests that under conditions other than those used in this
study, hBO-1 may exhibit a bystander effect. Due to the role hBD-1 has in innate
and adaptive immunity, the restoration of expression in cancer cells where it has
been lost may prove to be a useful antitumor therapy.

MATERIALS AND METHODS
MTT Cell Viability Assay

To examine the bystander effects of hBO-1 on prostate cancer cells, we
perfonned metabolic 3-[4,5-dimethylthiazol-2y1]-2,5-diphenyl tetrazolium brom ide
(MTT) assay. DU145 and PC3 cells were seeded onto a 96-well plate at 5 x10 3
cells per well. Twenty-four hours after seeding, fresh growth medium was added
to control cells, while test conditions were treated with medium exposed to
hPrEC cells for 24-48 hours. After incubation with the conditioned media for 24,
48, and 72 hours a MTT assay was performed according to the manufacturer's
instructions (Prom ega}. Reactions were performed three times in triplicate.

AD/EtBr Confocal Analysis

AO/EtBr staining was performed to identify changes in cell
membrane integrity as described previously.

Briefly, DU145 and LNCaP cells

were seeded onto 35mm dishes. Cells transfected with pvgRXR vector or hBO-1
plasmid were induced for 24 or 48 hours with media containing 10 fJM Pan A,
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while control cells received fresh growth media at each time point.

At the

appropriate time point, the media was collected and placed onto DU145 and
LNCaP cells seeded onto 2-chamber slides. The cells were incubated with the
conditioned medium for 24 or 48 hours prior to staining.

Then, cells were

washed once with PBS and stained with 2 ml of a mixture (1:1) of AD (Sigma, St.
Louis, MO) and EtBr (Promega) (5 Jjg/ml) solution for 5 min and were again
washed with PBS. Fluorescence was viewed by a Zeiss LSM 5 Pascal Varia 2
Laser Scanning Confocal Microscope (Carl Zeiss) under 40x magnification and
the images were collected and processed as previously mentioned.

Trypan Blue Exclusion

DU145 and LNCaP cells were plated on 60mm dishes and transfected
with pvgRXR vector or hBD-1 plasmid. Following induction for 24 hours with
media containing 10 JjM Pan A or fresh growth media for control cells, the media
was collected and place onto DU145 and LNCaP cells seeded into 6-well plates.
After incubation with the conditioned medium for 24 hours, the cells were washed
~

with PBS and collected. The cells were stained with a mixture (1:1) of cells and
PBS containing 0.4% Trypan Blue (Invitrogen). Cells were counted after a 5 min
incubation at RT as viable (no blue stain) or non-viable (blue stain) in four
quadrants of a hemocytometer. Data are presented as percent non-viable as
follows:

%

non-viable= # non-viable/total (viable+non-viable) x 100. Phase

contrast pictures of the field of cells on the hemocytometer were obtained and
~-

the images processed as previously described.
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Hoechst Stain

DU145, PC3 and LNCaP control cells or transfected with pvgRXR vector
or hBD-1 plasmid were induced for 24 and 48 hours with 10 J..IM Pon A or fresh
growth media (controls). Following each incubation period the medium was
collected from the plates, spun briefly and placed on DU145, PC3 or LNCaP
recipient cells. Recipient cells were exposed to the conditioned donor medium
for 24,48, or 72 hours prior to analysis, while donor cells received new media
containing 30pl of 1x Hoechst 33342 dye. After 5 min of incubation, cells were
analyzed under UV light on a Zeiss fluorescent microscope under 20x
magnification. Images were captured and processed as previously described.
The protocol was performed on recipient cells following the appropriate exposure
to conditioned medium with the addition of 15pl of 1x Hoechst 33342 dye.

Flow Cytometry

DU145 cells transfected with the hBD-1 expression system and control
cells were grown in 60-mm dishes· were induced for 24 and 48 hours with 10 IJM
Pan A or fresh growth media, respectively.

The donor cells were used to

generate conditioned media for recipient cells. Following each incubation period
the medium was collected from the donor plates, spun briefly and placed on
DU145 and LNCaP recipient cells.

Recipient cells were exposed to the

conditioned donor medium for 24, 48, or 72 hours prior to a wash with PBS. The
attached donor or recipient cells were harvested-by trypsinization and pelleted at
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4° C (1500 rpm) for 5 min, washed in PBS, and resuspended in 100 lJl PBS.
While vortexing or bubbling with a pipette, 2 ml of 70% EtOH was added dropwise. Samples were stored 1h to 3 days at 4° C. Then, the suspension was
washed with PBS and pelleted at 4° C (3000 rpm) for 5 min. The pellet was
resuspended in 100pl of PBS prior to the addition of 100pl RNase (Sigma,
1mg/ml) and 200pl of propidium iodide solution (1:100 dilution of a 1mg/ml

stock). Samples were vortexed and stored at 4° C for at least 30 min wrapped in
foil prior to flow analysis by FACscan (Becton Dickinson).

All reactions were

performed two times.

RESULTS
Effect of conditioned media on cell viability

To better understand the mechanism of action of hBD-1, it is important to
assay whether the peptide acts in an autocrine or paracrine manner. It is widely
accepted that hBD-1 is constitutively expressed by epithelial cell S90 , Several
groups have reported the secretion of hBD-1 peptide into the media of human
epithelial cell lines including gastrio (AGS)160, colon (HT-29 and Caco-2)161, and
gingival (HGEC)162, Therefore, normal prostate epithelial cells, hPrEC, were
used to determine if hBD-1 exhibits a bystander effect on neighboring cells
(Figure 5-1A).
Here, media exposed to hPrEC for 48 hours was collected and used to
treat DU145 and PC3 cells for 24,48, and 72 hours. MTT analysis of DU145
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Figure 5-1: Basic diagram of bystander studies~ (A) A diagram that
demonstrates the bystander assay perionned using conditioned media from
hPrEC. (8) A diagram illustrating the use of conditioned media from prostate
cancer cell lines induced for hBD-1 expression.
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~

24h
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48h
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72h

Figure 5-1: Basic diagram of bystander assays.
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cells following a 48h exposure to hPrEC conditioned media revealed mixed
results (Figure 5-2). It appears that the difference between control media and
conditioned media ranged from no to moderately significant. Therefore, alternate
methods were used to investigate whether hBD-1 exhibits a bystander effect on
adjacent cells.

Effect of conditioned media on membrane integrity

To test the possibility of hBD-1 exhibiting a bystander effect with an
alternate method, we used media conditioned by prostate cancer cells induced to
express hBD-1 (Figure 5-18). Since the proposed mechanism of action of
defensin peptides involves pore formation, recipient cells were exposed to the
conditioned media for 24 or 48 hours prior to analysis of membrane integrity by
confocal microscopy (Figure 5-3). Intact cells stained green due to the
fluorescence of membrane permeable AD, whi,le cells with compromised
membranes stained red due to the fluorescence of membrane impermeable EtBr.
When DU145 cells were treated with media conditioned by DU145 cells, there
was a slight accumulation of EtBr staining in hBD-1 exposed (A). However,
LNCaP cells treated with media conditioned by DU145 cells did not demonstrate
a difference in staining from control or pvgRXR exposed (8). Media conditioned

by LNCaP was also used to treat LNCaP and did not demonstrate a difference in
EtBr staining from pvgRXR exposed (C). This finding sl:lQgests that alterations to

119

Figure 5-2: Effect of conditioned media on cell viability_ An MTT assay was
perfonned to determine cell viability after 48h exposure to conditioned media
from hPrEC.
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121

Figure 5-3: Effect of conditioned media on membrane integrity. Membrane
integrity of recipient cells was analyzed by confocal microscopy 24 h after hBD-1
induction. (A) DU145 conditioned media on DU145 recipient cells. (B) DU145
conditioned media on LNCaP recipient cells. (C) LNCaP conditioned media on
LNCaP recipient cells. Green staining indicates the localization of AO, red
staining represents EtBr and yellow staining represents the co-localization of
both AO and EtBr. Size bars

= 10 j/M.
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Figure 5-3: Effect of conditioned media on membrane integrity.

123

membrane integrity may occur in response to exposure of hBD-1 containing
media in some cases.

Effect of conditioned medium on trypan blue exclusion

Similar to the previous experiment, trypan blue is a vital stain used to
selectively color dead cells blue, while viable cells exclude the dye. Since it has
been demonstrated that hBD-1 is cytotoxic to celis, dye exclusion was used to
assess the effect conditioned media had on other cells to test the possibility of a
bystander effect. As indicated in Figure 5-4, there was not a significant effect of
conditioned media from DU145 or LNCaP on recipient cell lines. However, there
was a minimal increase in hBD-1 exposed cells indicating a slight trend toward a
potential bystander effect.

Effect of conditioned media on the cell cycle

The cell cycle is comprised of a series of checkpoints and phases through
which proliferating cells progress. The cell cycle consists of the following: G 1 ,
presynthetic growth phase 1; S, DNA systhesis phase; G2 ; and M, mitotic phase.
Quiescent cells are in a state called Go, however, most tissues consist of cells at
various phases of the cell cycle.
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Figure 5-4: Analysis of dye exclusion after exposure to conditioned media .
The effect of hBD-1 conditioned media on DU145 and LNCaP prostate cancer
cells was quantified as percent non-viable under the various conditions.
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Figure 5-4: Analysis of dye exclusion after exposure to conditioned media.
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The most commonly utilized dye for DNA content and cell cycle analysis is PI,
which intercalates into the major groove of double-stranded DNA and produces a
highly fluorescent adduct. Here, FACS analysis was performed to assess
whether hBO-1 conditioned media had any effect on donor or recipient cells.
Neither the results at 24 hours (Figure 5-5) nor 48 hours (Figure 5-6) indicated a
difference from the negative control, pvgRXR.

Effect of conditioned media on cells

Since we have shown hBO-1 induces apoptotic cell death with expression,
Hoechst 33342 was used to assess the effect of hBD-1 on donors and recipients.
Hoechst dyes bind to AT-rich regions of DNA that can be excited with a UV
source. It has been observed that short exposures of cells to low concentrations
of Hoechst dye strongly labels apoptotic cells 163,164. Therefore, we utilized this
method as a method to assess the end-point of hBO-1 expression observed in
prostate cancer cell lines. Donor cells induced for hBD-1 expression
demonstrated a significant increase in condensed nuclei from pvgRXR and
controls (Figure 5-7). Media from the 24 hour donors was exposed to DU145
recipient cells for 24, 48, and 72 hours. We found that although there was not a
significant difference from pvgRXR and controls, there appears to be a trend
consistent with a potential effect (Figure 5-8). DU145 recipient cells exposed to
media from 48 hour donors demonstrated a slight, but i~_significant increase in
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Figure 5-5: Cell cycle analysis after treatment with 24h conditioned media.
The effect of 24 hour conditioned media on the cell cycle was analyzed by flow
cytometry. Data are presented as percentages of modeled events measured at
each phase.
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Figure 5-5: Cell cycle analysis after treatmer),t with 24h conditioned media.
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Figure 5-6: Cell cycle analysis after treatment with 48h conditioned media.
The effect of 48 hour conditioned media on the cell cycle was analyzed by flow
cytometry. Data are presented as percentages of modeled events measured at
each phase.
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Figure 5-6: Cell cycle analysis after treatment with 48h conditioned media.
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Figure 5-7: Analysis of apoptosis in donor cells. (A) Microscopic analysis of
condensed nuclei in DU145 cells induced for hBD-1 expression for 24 hours. (8)
Graphical representation demonstrating the percentage of condensed nuclei in
DU145 cells induced for hBD-1 expression for 24 hours.
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Figure 5-7: Analysis of apoptosis in donor cells.
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Figure 5-8: Analysis of apoptosis after exposure to 24h conditioned media.
(A) Microscopic analysis of condensed nuclei in DU145 cells exposed to 24h
conditioned media at 24; 48, and 72 hours. (8) Graphical representation
demonstrating the percentage of condensed nuclei in DU145 cells exposed to
24h conditioned media at 24, 48, and 72 hours.
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Figure 5-8: Analysis of apoptosis after exposure to 24h conditioned media.
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apoptotic nuclei (Figure 5-9). Additionally, similar results were found for PC3
cells under the same conditions (data not shown).

DISCUSSION
The field of tumor immunity has been rapidly expanding in recent years.
There is increasing evidence that altered immune function may not only
accompany, but even facilitate the development and progression of cancer. To
date, numerous AMPs and other host-defense molecules have been shown to
have altered expression profiles in a variety of cancers6 . 56.165.
Previously we demonstrated the high frequency of hBD-1 expression in
prostate and renal carcinomas6 . The cancer-specific cytotoxicity of hBD-1 was
recently shown in a renal cancer celiline 57 • In addition, our studies have
confirmed that late-stage prostate cancer cells induced to express hBD-1
undergo a caspase-mediated cell death, while normal prostate cells and earlystage prostate cancer cells do not56 .
It is known that hBD-1 exhibits antimicrobial properties by binding to the bacterial
membrane and forming pores that ultimately result in death 166 . However, the
exact mechanism by which hBD-1 exhibits cytotoxicity toward cancer cells is
unknown. To better understand the mechanism of cytotoxic action of hBD-1 in
human cancer cell lines, we designed experiments to elucidate whether the
secreted peptide acts in an autocrine or paracrine fashion.
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Figure 5-9: Analysis of apoptosis after exposure to 48h conditioned media.
(A) Microscopic analysis of condensed nuclei in DU145 cells exposed to 48h
conditioned media at 24,48, and 72 hours. (8) Graphical representation
demonstrating the percentage of condensed nuclei in DU145 cells exposed to
48h conditioned media at 24, 48, and 72 hours.
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Figure 5-9: Analysis of apoptosis after exposure to 48h conditioned media.
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Specifically, we performed an array of assays in an effort to determine if
hBD-1 exhibited a bystander effect on adjacent cells. In our system we were
unable to demonstrate a bystander effect attributed to the expression of hBD-1.
However, several assays resulted in data that indicates a slight trend toward a
potential bystander effect.
There are several reasons why a bystander effect was not observed within
our test parameters. The first possibility involves the proteolytic processing of
the peptide. It is known the functionally active protein in host defense is the 36
amino acid peptide81 , 118. Additionally, it has been shown that significant amounts
of hBD-1 peptide are released into the lumen of the kidneys as a 47 amino acid
pro-peptide that undergoes proteolytic cleavage to a variety of truncated
forms 118 . Although the microbicidal activity of other forms of hBD-1 was reduced
in some conditions, it has been shown that these effects were not observed with
the biologically active 36 amino acid peptide 74 . Given that the exact size of hBD1 peptide generated in our expression system is unknown, it is a possibility that
there is a decrease in biological activity due to proteolytic processing.
The observed trend toward a potential bystander effect may be due to the
expression system used to induce hBD-1 in the cell lines. hBD-1 was cloned into
the Ecdysone Inducible Mammalian Expression System (Invitrogen), a dual
vector system that permits the regulation of gene expression. In this system,
both subunits of a functional ecdysone receptor from Drosophila are
constitutively expressed from the regulator vector, pvgRXR. The ecdysoneresponsive promoter (p-Jl-HSP) that ultimately drives the expression of hBD-1 is
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located on the second inducible vector. In the presence of the inducer, Pon A,
the functional ecdysone receptor binds upstream of the ecdysone responsive
promoter and activates gene expression. Although expression is supposed to be
ligand-induced, it has been shown that this system is leaky and allows for gene
expression in the absence of the inducing agent167 .
Due to the leaky nature of the expression system, it was difficult to
generate stable clones in the prostate cancer cell lines since hBO-1 is cytotoxic
to them. Therefore, transient transfections were performed to evaluate hBD-1
effect on the cultured cells. Although an estimation of transfection efficiency was
completed to derive an average, there was variation between the experiments.
Taken together, it is possible that the optimal transfection efficiency in this
transient system was not achieved to observe a bystander effect.
A final reason for the lack of bystander effect in the methods tested may
be due to the concentration of hBD-1 present. It is believed that when a peptide

is selective for a cancer cell a threshold concentration must be reached prior to
membrane disruption 91 . In the methods used there was not a quantitative
analysis of hBD-1 in the conditioned media, thus, making it possible that the
difference in responses between donor and recipient cells may be due to altered
media concentrations of the peptide. Additionally, the experiments did not
assess the degradation of the peptide to see if this potentially contributed to a
decrease concentration of hBO-1 in the conditioned media exposed to recipient
cells.
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In summary, we utilized hPrEC which are believed to constitutively
express hBD-1 and prostate cancer cell lines induced to express hBD-1 to test
the possibility of a bystander effect. In donor DU145 and PC3 prostate cancer
cells induced for hBD-1 expression, a clear cytotoxic effect was observed.
However, the treatment of recipient cells with conditioned media did not generate
similar results. Data indicate that although there is not a bystander effect under
the conditions tested, there is a trend upward indicating the possibility of a
bystander effect. Therefore, it may be interesting to study the potential bystander
effect of hBD-1 under different conditions.
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CHAPTER 6
SUMMARY AND FUTURE DIRECTIONS
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Prostate cancer continues to be the most common non-cutaneous cancer
and a leading cause of death in American men 25 • A variety of factors increase
the risk for development of prostate cancer, including diet, environment and
genetics. Although the exact mechanism of prostate tumorigenesis is unknown,
it is known that the molecular pathogenesis involves a series of pre-malignant
changes that lead to the uncontrolled cell growth indicative of prostate cancer.

Currently there are limited treatment methods that improve survival
beyond localized prostate cancer153 . Additionally, the clinical outcome of
prostate cancer is closely related to the tumor grade and stage, with poorly
differentiated tumors having a poor prognosis 131. In prostate cancer patients,
tumor progression has been linked to an increase in immune suppression

6

.

It

has also been suggested that tumors escape destruction due to an imbalance
between immune activation and suppression during tumor growth 132. However,
little is known about specific components of the innate immune system that play
a role in prostate tumor suppression. Therefore, the emergence of new
molecular targets that have strong anti-tumor effects without corresponding host
toxicity may prove to be an essential treatment modality in prostate cancer.

The involvement of defensin proteins in cytotoxicity and cytolysis, with
respect to tumor immunity, is gaining more attention. Defensins are a family of 34 kDa polycationic peptides involved in host immunit/o. They are classified into
subfamilies, a-,

/3-, and 8-defensins, based on the connectivity of cysteine

residues in the precursor gene structure 74 . The a-defensins are predominantly
143

abundant in the granules of polymorphonuclear leukocytes and exhibit broad
spectrum antimicrobial activity against Gram-negative and Gram-positive
bacteria, fungi, and enveloped viruses 7S , 79. On the other hand, p-defensins have
been identified in epithelial cells and are mainly active against Gram-negative
bacteria and yeast60 ,77.

The core motif for p-defensins includes 9 highly conserved amino acid
residues that probably serve as essential components of the primary structural
motitB1, 168. To date, six hBDs have been identified that are constitutively
secreted, hBD-1, or induced for secretion, hBDs 2-6, at the epithelial cell
suriace84 ,85. Of particular interest in our lab was hBD-1, which was first isolated
from the plasma of patients with renal disease in 199581 . Several N-terminally
truncated molecular variants of hBD-1 have been identified from 36-47 amino
acids in length. However, the 36 amino acid peptide is considered the
biologically active form 74

Previously Donald et al have shown the cancer specific loss of hBD-1
expression in prostate and renal carcinoma tissue 6 . Specifically, 82% of the
malignant prostate tissue demonstrated little to no hBD-1 expression compared
to adjacent benign tissue 6 . In addition, the observed loss of expression occurred
as early as PIN with adjacent benign tissue displaying normal glandular staining
for hBD-1 6 .

These observations led to the hypothesis that hBD-1 may have anti-tumor
activities and that its loss may contribute to prostate tumorigenesis. In this study,
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we test the hypothesis that hBD-1 may have anti-tumor activities by
characterizing its function in prostate cancer. Initial screening of benign prostate
tissue and the primary prostate cell culture hPrEC revealed high levels of hBD-1
expression. However, we observed a decrease or loss of hBD-1 expression in
adjacent malignant prostate tissue, as well as in DU145, PC3 and LNCaP
prostate cancer cell lines.

Induction of hBD-1 expression in our prostate cancer cell lines caused a
significant reduction in cell viability and proliferation in the late-stage prostate
cancer cell lines, DU145 and PC3. To assess whether the effect was cytostatic
or cytotoxic, we performed FACS analysis to measure cell death. After inducing
hBD-1 in DU145 and PC3 cell lines, the number of cells undergoing early
apoptosis and late apoptosis/necrosis totaled 59% and 44%, respectively, by 48
hours. Our results demonstrated the cytotoxic activity of hBD-1 on DU145 and
PC3 prostate cancer cells.

The mechanism of cell death indicated in our cytotoxicity studies was
apoptosis. To better understand the actions of hBD-1 in prostate cancer cells,
we investigated whether hBD-1 induction resulted in caspase activation. Initial
studies indicated the general activation of caspases in DU145 and PC3 cells.
Analysis of specific caspases demonstrated that hBD-1 expression results in the
activation of caspases 3, 8, and 9. In addition, there were alterations in the
expression profiles of several pro- and anti-apoptotic factors. These findings
suggest that hBD-1 expression may playa key role in determining the fate of
cancer cells and, hence, tumor progression.
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The proposed mechanism of antimicrobial action of defensin peptides
involves the disruption of the microbial membrane due to the formation of
pores

80

•

To determine if hBD-1 expression altered the membrane integrity of the

prostate cancer cells, EtBr uptake was examined by confocal analysis. Our
results demonstrated permeable membranes in DU145 and PC3 cell induced for
hBD-1 expression, while LNCaP did not have observable membrane alterations.
This finding suggests that alterations to membrane integrity in response to hBD-1
expression differ between early- and late-stage prostate cancer cells.
Additionally, it provides the first line of evidence into the mechanism of hBD-1
induced cell death.

To further delineate the mechanism of hBD-1 cytotoxicity, we examined if
the death observed was due to a bystander effect. Several groups have
demonstrated the secretion of hBO-1 into the media of a variety of epithelial cell
lines160,161. Therefore, hPrEC generated conditioned media was used to
determine if hBO-1 exhibits a bystander effect. The results of the initial study
revealed a range from insignificant to significant reduction in cell viability after
exposure to the conditioned media. Due to the variation in the results and the
lack of concrete evidence supporting the secretion of hBD-1 by hPrEC, alternate
methods to generate conditioned media were employed.

As an alternate method to generate conditioned media, prostate cancer
cell lines were induced for hBD-1 expression and the media was collected at
various time points to treat non-hBD-1 expressing prostate cancer cells. We
have previously demonstrated that hBD-1 expression in DU145 and PC3 results
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in a decrease in cell viability, an increase in membrane permeability and
apoptosis. Therefore, we assessed recipient cells following treatment with
conditioned media by dye exclusion, AO/EtBr staining, and Hoechst staining to
observe the effects, if any, to cell vitality, membrane integrity and nuclear
condensation. Although the results did not indicate a bystander effect within the
experiment parameters, there was a minimal increase in staining in each of the
assays indicating a slight trend toward a potential bystander effect. In addition,
cell cycle analysis following treatment with hBD-1 conditioned media was
performed. However, the results indicated no difference from the negative
control pvgRXR conditioned media.

There are several reasons why a bystander effect was not attributed to the
expression of hBD-1 in our system. Since it is unknown what form of the peptide
is expressed in these experiments, it is possible that differences in the proteolytic
processing of the peptide have reduced the activity. Also, the concentration of
peptide in the media is unknown. It has been shown that synthetic hBD-1
peptide caused a decrease in cell viability in bladder cancer cells at 50pg/m1 57 .
The trend toward; but lack of, a bystander effect may be due to the fact that the
threshold concentration of hBD-1 peptides was never reached to see optimal
results. In addition, a significant limitation to concentration of hBO-1 in our
system is the transient nature of our transfections.

Taken together, our data support the hypothesis that hBD-1 is a tumor
suppressor gene. Also, the data indicate the loss of hBD-1 in the surrounding
tissue in may create an environment that promotes the progression of prostate
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cancer. Due to the decreased expression of a host defense peptide in cancer,
there is a suggestion that defensins may contribute to tumor immunity.
The anti-tumor effect of defensins is an emerging field. Preliminary
experiments by Huang et al. demonstrated the slower growth of tumors injected
with hBD-2 vectors compared to control possibly due to an antitumor effect of
hBD_2
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Also, others have shown the differential gene expression profiles of

defensins in a variety of cancers 115,116. Therefore, additional studies of the antitumor effect of defensins are necessary to delineate the specific contribution of
defensins to tumor immunity.
The scope of this study was limited to characterizing the effects of hBO-1
in prostate cancer cells. However, there are several key experiments that would
Significantly contribute this particular area of research. First, the generation of a
better expression system is essential. The ability to perform quality experiments
in the future will require stable clones that can be induced without accompanied
leakiness of gene expression. Also, a triple stain experiment to verify which cells
are undergoing apoptosis after exposure to hBD-1 containing media would
provide further insight into the cytotoxic mechanism of this defense peptide.
Ultimately, in vivo experiments that investigate the anti-timor effects of hBD-1 will
aid in determining the clinical relevance of our findings.
In summary, this data demonstrates the induction of hBD-1 expression
resulted in rapid cell death in the late-stage prostate cancer cell lines, PC3 and
DU145, but had no effect on the early-stage prostate cancer cell line, LNCaP.
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With this, we provide the experimental evidence that hBD-1 may playa specific
role in tumor suppression of advanced prostate cancer. Furthermore, these data
support the potential utility of hBD-1 as a therapeutic agent for late-stage
prostate cancer without cytotoxic effects to the host.
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